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Repair of Acute Myocardial Infarction by Human Stemness Factors Induced Pluripotent Stem Cells
Summary: Triggered nuclear reprogramming through ectopic transgene expression of stemness factors offers a revolutionary strategy for embryo-independent derivation of pluripotent stem cells from an ordinary adult source. Induced pluripotent stem cell (iPS) technology invalidates chronological age, reversing cell fate to reset an atavistic embryonic-like potential of somatic tissue. In this way, iPS have attained functions previously demonstrated only by natural embryonic stem cells to independently produce all tissue types and develop the complete organism within an embryonic environment. In the present study, fibroblasts redirected by a foursome of human stemness factors, OCT3/4, SOX2, KLF4, and c-MYC, acquired bona fide pluripotent features ensuring de novo tissue replacement in embryonic and adult host environments. Head-to-head comparison between parental fibroblasts and reprogrammed progeny established the therapeutic value for cardiac tissue regeneration in a setting of ischemic heart disease. Specifically, transplantation of iPS in the acutely infarcted myocardium yielded structural and functional repair to secure performance recovery as qualified clones contributed to in vivo tissue reconstruction with "on-demand" cardiovasculogenesis. Although the full clinical impact of iPS-based technology will be revealed when safeguards are fully validated, the proof-ofprinciple study here establishes the practical application of bioengineered stem cells to respond to the ischemic myocardium and heal the damaged areas with iPS-derived integrated functional tissues. Therefore, converting self-derived fibroblasts, which are main contributors to postischemic scar, into reparative progenitors can now be considered a goal of regenerative medicine to individualize treatment algorithms for multilineage cardiovascular repair.
Conclusion: Fibroblasts reprogrammed by human stemness factors thus acquire the potential to repair acute myocardial infarction, establishing iPS in the treatment of heart disease. 1
Cardiomyocyte Differentiation of Human Induced Pluripotent Stem Cells
Summary: Cell-replacement therapy is emerging as a novel experimental therapeutic paradigm for myocardial repair/regeneration but is hampered by the limited sources of autologous cardiomyocytes. The breakthrough technology, allowing the reprogramming of adult human fibroblasts with a set of transcription factor into pluripotent stem cell lines (induced pluripotent stem [iPS] cells), may provide a possible solution to the aforementioned cell-sourcing problem. In the present study, we describe the in vitro differentiation of human iPS (hiPS) cells into the cardiac lineage and demonstrate that the molecular events characterizing this differentiation process parallel previously reported in vitro and in vivo cardiomyogenic models. The generated hiPS-derived myocytes displayed molecular, structural, and functional properties of early-stage human cardiomyocytes and responded appropriately to adrenergic and cholinergic signaling. In addition, the hips differentiating system was not limited to the generation of isolated cardiomyocytes; rather, a functional cardiomyocyte syncytium was established with stable pacemaker activity and action potential propagation. Finally, proof-of-concept pharmacological studies demonstrated the potential of the hiPS cell-derived cardiac tissue to serve as a unique platform for individualized drug testing and specifically for "QT screening." In conclusion, the ability to generate a reproducible hiPS-cardiomyocyte differentiation system may bring unique value to the emerging field of personalized medicine: for the establishment of patient/disease-specific disease models, for drug screening and target validation, and for the establishment of future autologous myocardial cell-replacement therapies.
Conclusion: hiPS cells can differentiate into myocytes with cardiacspecific molecular, structural, and functional properties. These results, coupled with the potential of this technology to generate patient-specific hiPS lines, hold great promise for the development of in vitro models of cardiac genetic disorders, for drug discovery and testing, and for the emerging field of cardiovascular regenerative medicine. 2
Ambient Air Pollution Exaggerates Adipose Inflammation and Insulin Resistance in a Mouse Model of Diet-Induced Obesity
Summary: Obesity and type 2 diabetes represent chronic low-grade inflammatory states that have both genetic and environmental determinants. Although the role of diet and exercise as environmental determinants is defined, the interaction between particulate air pollution (PM2.5) and other metabolic determinants of obesity/ insulin resistance has not yet been elucidated. In this experiment, we exposed C57BL/6 mice fed high-fat chow to concentrated ambient PM2.5 or filtered air for 24 weeks and demonstrated that PM2.5exposed mice exhibited marked whole-body insulin resistance, increased visceral adiposity and inflammation, vascular relaxation abnormalities, and enhanced monocyte adhesion to microcirculatory beds. Our findings provide new insights into a potential role for PM2.5 exposure in the pathogenesis of diabetes/insulin resistance and further our understanding of how inhaled particulates may modulate inflammatory responses in distant target organs.
MicroRNA-320 Is Involved in the Regulation of Cardiac Ischemia/Reperfusion Injury by Targeting Heat-Shock Protein 20
Summary: MicroRNAs (miRNAs) are a class of small noncoding RNAs with important posttranscriptional regulatory functions. Recent data suggest that miRNAs are aberrantly expressed in many human diseases including cardiovascular disease, which leads to an increasing interest in miRNA regulation as a therapeutic and diagnostic approach. Of note, multiple genes/proteins have been shown to be aberrantly expressed in infarcted hearts, which are responsible for cardiac remodeling after ischemia/reperfusion (I/R). In the present study, we used microarrays to profile the expression of 640 probed miRNAs in murine hearts on I/R in vivo and ex vivo. Several miRNAs were differentially expressed between shams and I/R hearts, with miR-320 showing downregulation consistently in I/R hearts ex vivo and in vivo relative to the shams. Gain-of-function and loss-of-function approaches were employed in cultured adult rat cardiomyocytes and in mouse hearts to investigate the functional roles of miR-320. Our data indicate that the increased levels of miR-320 may be responsible for cardiac I/R injury, whereas downregulation of miR-320 may be protective. Administration of antagomir-320, which specifically knocked down endogenous miR-320, significantly decreased cardiac infarction size. Thus, systemically or locally applied mimic or inhibitory miRNA molecules (ie, antagomir) that influence specific cardiac miRNAs may finally open novel miRNA-based therapies for heart disease.
Conclusion: Our data demonstrate that miR-320 is involved in the regulation of I/R-induced cardiac injury and dysfunction via antithetical regulation of heat-shock protein 20. Thus, miR-320 may constitute a new therapeutic target for ischemic heart diseases. 4
Functional Mesenchymal Stem Cells Derived From Human Induced Pluripotent Stem Cells Attenuate Limb Ischemia in Mice
Summary: Despite the initial encouraging results of preclinical and clinical studies, mesenchymal stem cells (MSCs) derived from adult tissue such as bone marrow have a limited proliferation and differentiation potential for tissue repair in ischemic disease. More important, aging significantly impairs their survival and differentiation potential and thus limits their therapeutic efficacy. Recent breakthrough in the generation of induced pluripotent stem cells (iPSCs) offers the possibility to obtain a high yield of patient-specific MSCs. In this study, we demonstrate that functional MSCs can be directly generated from iPSCs (iPSC-MSCs). Transplantation of iPSC-MSCs into mice achieved a more beneficial effect than adult bone marrow-derived MSCs in the attenuation of severe limb ischemia. This greater potential of iPSC-MSCs may be attributable to their superior survival and engraftment via de novo vascular and muscle differentiation and paracrine mechanisms. Our study suggests that functional MSCs can be generated from human iPSCs and have the potential to treat ischemic disease in a patient-specific, cost-effective, and batch-to-batch-consistent manner.
Conclusion: MSCs can be clonally generated, beginning at a singlecell level, from human iPSCs. Patient-specific iPSC-MSCs can be prepared as an "off-the-shelf" format for the treatment of tissue ischemia. 5
Myocardial Ischemia/Reperfusion Injury Is Mediated by Leukocytic Toll-Like Receptor-2 and Reduced by Systemic Administration of a Novel Anti-Toll-Like Receptor-2 Antibody
Summary: Over the past few decades, many molecular targets have been studied to limit the excessive tissue loss that occurs during the reperfusion phase after ischemia. This so-called myocardial ische-mia/reperfusion injury limits the full potential of reperfusion therapy. Unfortunately, successful clinical translation of preclinical promises remains to be established. Our understanding of the pathogenesis of myocardial ischemia/reperfusion injury became much clearer with the discovery of Toll-like receptors (TLRs). The role of innate immunity in cardiac ischemia appeared to be more pivotal than we thought. More important, TLRs hold great promise as a therapeutic target within the innate immune system, also beyond cardiac ischemia, without affecting host defense or proper scar formation after infarction. In the present study, we show the first therapeutic application of an anti-TLR2 antibody after myocardial ischemia and reperfusion. We found that circulating TLR2 mediates myocardial ischemia/reperfusion injury. Administration of a TLR2 antagonist just 5 minutes before reperfusion reduces infarct size and improves cardiac performance and geometry. Furthermore, antagonizing TLR2 reduces inflammation and cell death after infarction. Our results reappraised the critical role of TLRs in cardiac ischemia and elucidated the mechanisms by which TLR2 mediates myocardial ischemia/reperfusion injury. Our results establish TLR2 as a novel therapeutic target for the treatment of acute myocardial infarction, even when it is initiated in the late ischemic period. For this reason, we provide a rationale for anti-TLR2 treatment initiated either in the ambulance or in the catheterization laboratory before reperfusion.
Conclusion: Circulating TLR2 expression mediates myocardial ischemia/reperfusion injury. Antagonizing TLR2 just 5 minutes before reperfusion reduces infarct size and preserves cardiac function and geometry. Anti-TLR2 therapy exerts its action by reducing leukocyte influx, cytokine production, and proapoptotic signaling. Hence, monoclonal anti-TLR2 antibody is a potential candidate as an adjunctive for reperfusion therapy in patients with myocardial infarction. 6 
Anthracycline Cardiomyopathy Is Mediated by Depletion of the Cardiac Stem Cell Pool and Is Rescued by Restoration of Progenitor Cell Function
Summary: The mechanisms by which anthracyclines lead to the development of dilated cardiomyopathy in cancer patients are currently unknown. The work presented in this study raises the possibility that doxorubicin-induced cardiac failure is a stem cell disease mediated by a severe loss of resident cardiac progenitor cells (CPCs). Doxorubicin results in CPC apoptosis, which with time affects myocardial homeostasis and tissue repair. The dramatic reduction in the pool of CPCs conditions myocyte renewal, which promotes the accumulation of senescent, poorly functioning cardiomyocytes. I n the long term, these abnormalities in cardiac structure and myocyte performance markedly impair ventricular hemodynamics and the likelihood of animal survival. Notably, repopulation assays with syngeneic CPCs rescue the cardiac phenotype and largely restore the functional properties of the diseased heart. Although extreme caution must be exercised in the translation of these animal studies to humans, the possibility is raised that myocardial biopsy samples could be obtained before antineoplastic drugs are given to cancer patients. Autologous CPCs could be isolated and expanded from these myocardial samples for the treatment of heart failure in individuals who are particularly sensitive to the cardiotoxicity of chemotherapeutic agents.
Conclusion:
Our results raise the possibility that autologous CPCs can be obtained before antineoplastic drugs are given to cancer patients and subsequently administered to individuals who are particularly sensitive to the cardiotoxicity of these agents for prevention or management of heart failure. 7 lying the aging-induced attenuation of endothelial functions are unknown. On the basis of recent evidence, we hypothesized that microRNAs, a class of endogenous, small, noncoding, singlestranded RNAs of approximately 22 nucleotides that are known to negatively regulate gene expression, may be a cause of endothelial dysfunction. In the present study, we used a model of endothelial senescence to identify microRNAs associated with the aging process and to recognize their potential targets. We found that a particular microRNA, miR-217, is progressively expressed in endothelial cells during senescence. In silico analysis indicated that silent information regulator 1 (SirT1) is a potential target of miR-217. SirT1 is an NAD ϩ-dependent deacetylase that regulates gene expression and exerts protective effects against endothelial dysfunction and metabolic syndrome. SirT1 action is lost during aging, but the cause of the age-related decline of SirT1 is unknown. Thus, in the present studies, we sought to address whether endothelial senescence is determined by a miR-217-dependent SirT1 loss of function. We observed that miR-217 inhibits SirT1 function in endothelial cells, specifically by reducing its ability to modulate the function of a transcription factor called FoxO1 that is involved in angiogenesis, apoptosis, and stress resistance. The inhibition of miR-217 rescues the phenotype of senescent endothelial cells. The evidence for such a miR-217-SirT1-FoxO1 pathway in atherosclerotic plaque from human donors has clear clinical implications for the possibility of interfering with miR-217 by use of treatments to antagonize its function in the endothelium of patients.
Conclusion: Our data pinpoint miR-217 as an endogenous inhibitor of SirT1, which promotes endothelial senescence and is potentially amenable to therapeutic manipulation for prevention of endothelial dysfunction in metabolic disorders. 8 
Reciprocal Regulation of Myocardial microRNAs and Messenger RNA in Human Cardiomyopathy and Reversal of the microRNA Signature by Biomechanical Support
Summary: Prognosis in heart failure is notoriously difficult to assess. Interindividual variability in disease susceptibility, course, and response to therapy is a major problem for physicians, their patients, and the healthcare system in general. Improved metrics for categorizing patients on the basis of relative risk and benefit for particular treatment strategies could greatly facilitate clinical decision making. Toward this end, transcriptional profiling of myocardial messenger RNA (mRNA) has been used in attempts to identify unique genomic "signatures" for heart failure of different causes and, more importantly, different prognoses. However, these efforts have met with limited success, in part because the mRNA signature for end-stage heart failure does not adequately discriminate between ischemic and nonischemic cardiomyopathy or between hearts with poor function versus those with better function. The latter functional analyses are based on mRNA profiling of hearts with and without mechanical unloading from left ventricular assist devices, which markedly improve ventricular ejection performance and, in rare instances, facilitate longterm myocardial recovery after device removal. We identified a likely molecular signature for this myocardial "recovery" phenotype using microarray technology to comprehensively assay both microRNA and mRNA levels from 38 normal, failing, or left ventricular assist devicetreated hearts. Although neither mRNA profile nor microRNA profile alone provided acceptable specificity and sensitivity to differentiate the 3 categories of hearts, combining the 2 molecular signatures correctly classified 22 of 23 samples. These studies reveal a promising approach for individual genomic profiling of failing myocardium to improve clinical prognostication.
Conclusion:
These results show that miRs are more sensitive than mRNAs to the acute functional status of end-stage heart failure, consistent with important functions for regulated miRs in the myocardial response to stress. Combined miR and mRNA profiling may have superior potential as a diagnostic and prognostic test in end-stage cardiomyopathy. 9
Contribution of Impaired Myocardial Insulin Signaling to Mitochondrial Dysfunction and Oxidative Stress in the Heart
Summary: Obesity and diabetes mellitus may increase the risk of heart failure. The mechanisms are multifactorial, but recent studies have implicated a potential role for mitochondrial dysfunction. Studies in animal models of obesity and type 2 diabetes mellitus have suggested that insulin resistance develops in the myocardium. However, the consequences of insulin resistance in the heart are incompletely understood. The present study sought to determine whether impaired myocardial insulin signaling could impair mitochondrial function in the heart. Using genetically engineered mice with deletion of insulin receptors in cardiomyocytes, we show that impaired myocardial insulin signaling leads to multiple mitochondrial defects that include reduced oxygen consumption and ATP synthesis, reduced levels of mitochondrial enzymes that regulate pyruvate and fatty acid metabolism, and decreased content of citric acid cycle (tricarboxylic acid) proteins. Insulin signaling also regulates the expression of genes such as peroxisome proliferator-activated receptor-_ in the heart, which controls the capacity of mitochondria to oxidize fatty acids. In addition, mitochondria from hearts with defective insulin signaling demonstrate evidence of oxidative stress. This study identifies novel roles for insulin signal transduction in the regulation of cardiac mitochondrial function and identifies mechanisms that could potentially contribute to myocardial dysfunction when the heart becomes insulin resistant.
Conclusion: Impaired myocardial insulin signaling promotes oxidative stress and mitochondrial uncoupling, which, together with reduced tricarboxylic acid and fatty acid oxidative capacity, impairs mitochondrial energetics. This study identifies specific contributions of impaired insulin action to mitochondrial dysfunction in the heart. 10
Inhibiting Mitochondrial Fission Protects the Heart Against Ischemia/Reperfusion Injury
Summary: Despite optimal therapy, clinical outcomes in patients with coronary heart disease can be further improved by the discovery of new therapeutic strategies for protecting the heart from ischemia/ reperfusion injury. In this respect, in the present study, we have demonstrated that the modulation of mitochondrial morphology in the heart may provide a novel therapeutic strategy for cardioprotection. Specifically, we have demonstrated that inhibiting mitochondrial fission protected the heart by inhibiting the opening of the mitochondrial permeability transition pore, a critical mediator of ischemia/reperfusion injury. As a cardioprotective strategy, inhibition of mitochondrial fission may be induced through the pharmacological manipulation of mitochondrial morphology. In the present study, the in vivo pharmacological inhibition of the mitochondrial fission protein dynamin-related protein 1 with the small molecule inhibitor mdivi-1 reduced myocardial infarct size in the adult murine heart. The discovery of other novel compounds capable of inhibiting mitochondrial fission proteins such as dynamin-related protein 1 or activating mitochondrial fusion proteins such as mitofusin 1, mitofusin 2 or optic atrophy protein 1 may in the future be used to block mitochondrial fission in the clinical settings of acute ischemia/ reperfusion injury to reduce myocardial injury and infarct size in patients undergoing cardiac bypass surgery or patients presenting with a myocardial infarction, respectively, and to improve clinical outcomes in patients with coronary heart disease.
Conclusion: Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury, suggesting a novel pharmacological strategy for cardioprotection. 11 Although LVH is a compensatory mechanism for increased afterload in the setting of hypertension and aortic valve stenosis, LVH also involves the inhibition of cardiomyocyte antihypertrophic molecular signals. One of these antihypertrophic signals involves the hierarchical LKB1/AMPK energy-sensing pathway, which is able to inhibit the protein synthesis that is necessary for the development of LVH. Here, we provide evidence that inhibition of the LKB1/AMPK signaling axis is associated with LVH in a well-established rat model of hypertension and cardiac hypertrophy. We also show that this inhibition is due to a direct modification of LKB1 by the electrophilic lipid peroxidation byproduct 4-hydroxy-2-nonenal (HNE). Because HNE levels are elevated during hypertension, our study identifies a novel molecular mechanism that may contribute to the pathogenesis of LVH. Furthermore, we provide evidence that pharmacological targeting of this pathway may be a potential therapy for pathological LVH. Indeed, we show that administration of resveratrol to hypertensive rats reduces cardiac HNE levels, prevents the inhibition of the LKB1/AMPK signaling pathway, and subsequently inhibits signals controlling protein synthesis. As a result, cardiac hypertrophy is lessened in these hypertensive rats even in the absence of any decreases in blood pressure or LV performance. Overall, our results suggest that resveratrol, analogues of resveratrol, or possibly any agent that targets the LKB1/AMPK signaling axis could be a potential adjunct therapy to improve LV remodeling in hypertensive patients or in patients with established LVH.
Conclusion:
Our data identify a molecular mechanism in the cardiomyocyte involving the oxidative stress-derived lipid peroxidation byproduct HNE and the LKB1/AMPK signaling pathway that contributes to the development of left ventricular hypertrophy. We also suggest that resveratrol may be a potential therapy for patients at risk for developing pathological cardiac hypertrophy by preventing this prohypertrophic process. 12
Acute Doxorubicin Cardiotoxicity Is Associated With p53-Induced Inhibition of the Mammalian Target of Rapamycin Pathway
Summary: Anthracyclines are widely used and highly successful anticancer chemotherapeutic drugs. Unfortunately, these drugs also cause acute cardiotoxicity, such as arrhythmia and transient depression of left ventricular function, and higher cumulative doses are associated with late-onset refractory cardiomyopathy and heart failure. Because anthracyclines can interfere with many different intracellular processes, it has proven difficult to determine the exact mechanisms that give rise to acute versus chronic cardiotoxicity. This study examined acute cardiotoxicity in mice treated with the anthracycline doxorubicin. Treated mice exhibited a marked decrease in cardiac function acutely that was accompanied by a reduction in cardiac mass. Molecular analyses suggested that doxorubicin treatment increased levels of the tumor suppressor protein p53, which in turn inhibited the activity of mammalian target of rapamycin (mTOR). Inhibition of mTOR activity is predicted to decrease the translation of new proteins. In support of this mechanism, genetically modified mice expressing either dominantinterfering p53 or constitutively active mTOR exhibited normal cardiac function and mass after doxorubicin treatment. Interestingly, rescue of cardiac function and structure during acute cardiotoxicity was not associated with reduction of doxorubicin-induced cardiomyocyte apoptosis. These data suggest that coadministration of mTOR activators might decrease acute doxorubicin cardiotoxicity, thereby permitting a higher dose of drug per treatment. If so, administration of fewer doses of anthracycline at higher levels might be a more effective anticancer strategy. This approach may also allow lower cumulative doses, which would reduce the incidence of late-onset refractory cardiomyopathy.
Conclusion: These data suggest that doxorubicin treatment induces acute cardiac dysfunction and reduces cardiac mass via p53dependent inhibition of mTOR signaling and that loss of myocardial mass, and not cardiomyocyte apoptosis, is the major contributor to acute doxorubicin cardiotoxicity. 13
Increased Glucose Uptake and Oxidation in Mouse Hearts Prevent High Fatty Acid Oxidation but Cause Cardiac Dysfunction in Diet-Induced Obesity
Summary: The heart requires constant and substantial energy supply for continuous pumping and thus has developed an elaborate metabolic network for using all carbon substrates, including carbohydrates, fatty acids, ketones, and amino acids. Chronic shift of myocardial substrate preference has been noted in many diseases such as diabetes and heart failure. However, the underlying mechanisms and the functional consequence of the shift are poorly understood. The present study demonstrates that chronic changes in substrate availability induce molecular remodeling of multiple metabolic pathways by altering expressions and activities of key regulatory proteins. The remodeling allows a long-term shift of substrate preference while maintaining cardiac energetic and function. However, the new homeostasis is established at the expense of network flexibility. In our study, the transgenic mouse model with enhanced glucose uptake, glycolysis, and glucose oxidation in the hearts shows complete adaptation to a high-intracellular-glucose milieu. However, failure to upregulate fatty acid oxidation in the transgenic hearts during diet-induced obesity results in increased oxidative stress and contractile dysfunction. Thus, this study cautions against the simple views that "high glucose oxidation is beneficial" and "high fatty acid oxidation is detrimental." Instead, these observations suggest that inflexibility of the metabolic network in the heart caused by chronic metabolic diseases forms a basis for accelerated deterioration when other pathological conditions superimpose.
Conclusion:
We have demonstrated that chronic increases in myocardial glucose uptake and oxidation reduce the metabolic flexibility and render the heart susceptible to contractile dysfunction. 14
Reciprocal Regulation of MicroRNA-1 and Insulin-Like Growth Factor-1 Signal Transduction Cascade in Cardiac and Skeletal Muscle in Physiological and Pathological Conditions
Summary: MicroRNAs (miRNAs/miRs) are small conserved RNA molecules of 22 nucleotides that negatively modulate gene expression primarily through base paring to the 3 untranslated region of target messenger RNAs. The muscle-specific miR-1 has been implicated in cardiac hypertrophy, heart development, cardiac stem cell differentiation, and arrhythmias through targeting of regulatory proteins. In this study, we investigated the molecular mechanisms through which miR-1 intervenes in regulation of cardiac and skeletal muscle cell growth and differentiation. We demonstrate that miR-1 controls the expression of insulin-like growth factor-1 (IGF-1) and IGF-1 receptor protein levels by translation. The IGF-1 pathway is critically involved in many aspects of cardiac development and cardiac function. We found that in conditions in which miR-1 is decreased, such as cardiac hypertrophy, IGF-1 is increased; the regulation is reciprocal because IGF-1 stimulation leads to downregulation of miR-1 levels. This effect is dependent on IGF-1 inhibition of the Foxo3 transcription factor, which regulates miR-1 promoter activity. The clinical relevance of these observations is demonstrated by analyzing the expression of miR-1 in cardiac biopsies of patients with acromegaly, a condition in which growth hormone and IGF-1 are overproduced and cardiac myocyte size is dramatically increased; miR-1 levels inversely correlate with echocardiographic parameters of cardiac mass in these patients. Our results add information in regard to the manner in which the IGF-1 pathway regulates cardiac function, demonstrating the role of miR-1 in response to cardiac stress and hypertrophy.
Conclusion:
Our results reveal a critical role of microRNA-1 in mediating the effects of the IGF-1 pathway and demonstrate a feedback loop between miR-1 expression and the IGF-1 signal transduction cascade. 15
Vascular Endothelial Growth Factor-B Induces Myocardium-Specific Angiogenesis and Arteriogenesis via Vascular Endothelial Growth Factor Receptor-1-and Neuropilin Receptor-1-Dependent Mechanisms
Summary: Severe coronary heart disease is still a leading cause of death in developed countries in spite of improved management of risk factors and effective treatments. A steadily increasing number of patients fall into a category in which currently available revascularization techniques cannot be applied. Thus, there is a clear need to develop efficient, minimally invasive procedures for the treatment of these no-option patients. In this study, we report a heart-specific angiogenic gene therapy approach for the treatment of myocardial ischemia. An adenovirus encoding vascular endothelial growth factor-B (VEGF-B) was injected directly into the ischemic area in the left ventricular wall via an injection catheter. In this pig model of acute myocardial infarction, VEGF-B induced growth of neovessels in the infarction edge, which rescued hibernating myocardium in the periinfarction zone and induced growth of angiographically visible collateral vessels to form a biological bypass to transport blood to the infarction edge. VEGF-B also increased blood flow and increased ejection fraction in the ischemic heart. Moreover, VEGF-B induced metabolic changes by increasing glycogen accumulation, fatty acid transport, and lipid content in cardiomyocytes. VEGF-B also inhibited apoptosis of cardiomyocytes, thus protecting the cells from ischemia. These effects were mediated at least in part by a novel mechanism via VEGF receptor-1 activation of neuropilin receptor-1 and consequent activation of G-protein-mediated signaling.
Conclusion: VEGF-B186 displayed strikingly distinct effects compared with other VEGFs. These effects may be mediated at least in part via a G-protein signaling pathway. Tissue-specificity, high efficiency in ischemic myocardium, and induction of arteriogenesis and antiapoptotic and metabolic effects make AdVEGF-B186 a promising candidate for the treatment of myocardial ischemia. 16 
Multipotent Mesenchymal Stem Cells Acquire a Lymphendothelial Phenotype and Enhance Lymphatic Regeneration In Vivo
Summary: In the present study, we assessed the ability of wellcharacterized mesenchymal stem cell (MSC) lines to acquire a lymphatic phenotype in vitro and in vivo. To date, the contribution of stem cells to lymphangiogenesis is not well understood, and the available reports describe conflicting evidence. However, we were able to demonstrate that MSCs are capable of expressing a lymphatic phenotype when exposed to lymph-inductive media and purified vascular endothelial growth factor-C. Migratory activity toward vascular endothelial growth factor-C in vitro suggests homing capability in vivo. Restoration of lymphatic drainage after injection of MSCs in a lymphedema model indicates that MSCs play a role in lymphatic regeneration. The experiments presented strongly suggest that peripheral blood-derived stem cells are involved in lymphatic regeneration after surgical disruption of lymphatic channels. The results suggest that these relatively easily accessible peripheral blood-derived stem cells may be of therapeutic value in patients with chronic or acute lymphatic edema. The observed involvement of MSCs in restoration of lymphatic drainage leads to further questions about the role of MSCs in tumor-associated lymphangiogenesis and lymphatic endothelial cell-secreted factors that drive MSCs toward lymphatic differentiation.
Conclusion: MSCs were capable of expressing a lymphatic phenotype when exposed to lymph-inductive media and purified VEGF-C. Migratory activity toward VEGF-C in vitro suggests homing capability in vivo. Restoration of lymphatic drainage after injection of MSCs in a lymphedema model indicates that MSCs play a role in lymphatic regeneration. The potential clinical application of MSC in wound healing and reduction of lymphatic edema warrants further research. 17
Cardiac Progenitor Cells and Biotinylated Insulin-Like Growth Factor-1 Nanofibers Improve Endogenous and Exogenous Myocardial Regeneration After Infarction
Summary: Myocardial infarction is characterized by an extensive loss of cardiomyocytes and vascular structures, and the size of the initial insult is a critical determinant of the evolution of the postinfarcted heart and negative ventricular remodeling. Resident cardiac progenitor cells (CPCs) do not migrate spontaneously to the area of damage, and healing is associated with scar formation and alterations in cardiac structure and function. Recent clinical trials have suggested that the intracoronary delivery or intramyocardial injection of adult autologous progenitor cells may have a beneficial effect on the treatment of acute and chronic heart failure in patients. At least 3 possibilities have been advanced: (1) myocardial regeneration mediated by differentiation of the delivered cells; (2) paracrine effects triggered by activation of resident progenitor cells; and (3) a combination of both processes. In the present study, we tested whether the local administration of CPCs together with insulin-like growth factor-1 tethered to self-assembling peptide nanofibers enhanced the activation and differentiation of exogenous and endogenous CPCs potentiating cardiac repair after infarction. By this strategy, the growth and differentiation of the delivered CPCs were markedly increased, and these positive aspects of myocardial regeneration were accompanied by intense recruitment of resident CPCs. This pool of tissue-specific progenitor cells rapidly acquired the adult cardiomyocyte phenotype. In comparison with infarcts treated with CPCs alone, combination therapy resulted in a greater recovery of myocardial structure and ventricular performance. Collectively, our observations point to the potential therapeutic import of CPCs and nanofibers engineered to deliver growth factors for the management of ischemic cardiomyopathy in humans.
Conclusuion: The addition of nanofiber-mediated insulin-like growth factor-1 delivery to CPC therapy improved in part the recovery of myocardial structure and function after infarction. 18
Dual Angiogenic and Neurotrophic Effects of Bone Marrow-Derived Endothelial Progenitor Cells on Diabetic Neuropathy
Summary: In the United States alone, Ͼ18 million people suffer from diabetes mellitus. Peripheral neuropathy is the most common complication of diabetes mellitus, affecting up to 60% of longstanding diabetic patients. Diabetic neuropathy (DN) commonly manifests with loss of sensation in the feet, frequently leading to foot problems such as ulcers. Despite a continuous increase in the incidence of diabetes and DN, current treatments have yet to effectively treat DN. Recent evidence suggests that DN is causally related to impaired angiogenesis and deficient neurotrophic factors. Endothelial progenitor cells exist in peripheral blood and bone marrow. Therapeutically, preclinical and clinical pilot studies have demonstrated that endothelial progenitor cells are effective in repairing various cardiovascular diseases via differentiation into new vessels and production of angiogenic and neurotrophic factors. In this study, we demonstrate that local injection of endothelial progenitor cells reversed functional impairments of DN in experimental DN by augmenting neovascularization and providing angiogenic and neurotrophic factors in diabetic nerves. Our study suggests a novel therapeutic strategy, the application of stem/progenitor cell therapy, for DN and provides new insight into the pathophysiological features of DN. Considering that DN is frequently combined with diabetic foot ulcers, limb ischemia, or both, an approach that uses endothelial progenitor cells could have additional clinical benefits for treating complicated DN.
Conclusion:
We demonstrate for the first time that bone marrowderived endothelial progenitor cells (EPCs) could reverse various manifestations of diabetic neuropathy. These therapeutic effects were mediated by direct augmentation of neovascularization in peripheral nerves through long-term and preferential engraftment of EPCs in nerves and particularly vasa nervorum and their paracrine effects. These findings suggest that EPC transplantation could represent an innovative therapeutic option for treating diabetic neuropathy. 19
Sca-1؉ Stem Cell Survival and Engraftment in the Infarcted Heart: Dual Role for Preconditioning-Induced Connexin-43
Summary: The hostile microenvironment of ischemic myocardium causes extensive cell death. Preconditioning of stem cells by shortterm treatment with growth factor is shown here as a simple, safe, effective, and potentially therapeutic intervention to promote their survival after engraftment. Insulin-like growth factor-1 preconditioning also promoted connexin-43 translocation to the mitochondria. Studies are being performed to investigate a possible role for the mitochondrial connexin-43 in cytoprotection. The potential benefits of preconditioning the stem cells before transplantation are enormous and will revolutionize our thinking about strategies for cell-based therapies.
Conclusion: Preconditioning with insulin-like growth factor-1 reprograms Sca-1ϩ for prosurvival signaling and cardiomyogenic differentiation with an important role for connexin-43 in this process. 20
Genetic Deletion of Myostatin From the Heart Prevents Skeletal Muscle Atrophy in Heart Failure
Summary: The prevalence of chronic heart failure is steadily increasing in our population. Individuals suffering from this disease face high rates of mortality (which were reported to be as high as 50% in 5 years) and dire symptoms like dyspnea, edema, exercise intolerance, and muscle loss. Skeletal muscle atrophy occurs in up to 68% of patients with heart failure and has been identified as a strong independent risk factor for mortality. Despite these facts, the cause of muscle wasting in heart failure is unclear, and a targeted treatment option is lacking. In this study, we show that the mouse heart, when exposed to pathological hemodynamic burden consistent with heart failure, releases the protein myostatin, a well-known inhibitor of skeletal muscle growth, into the systemic circulation. Genetic ablation of myostatin specifically in the heart prevented skeletal muscle atrophy when heart failure was induced. Antithetically, genetically modified mice with enhanced myostatin expression in the myocardium showed skeletal muscle rarefaction, indicating that cardiac myostatin is sufficient to induce skeletal muscle wasting. Therapeutically, injection of a myostatin-blocking antibody in mice with preexisting heart failure preserved muscle mass. Thus, myostatin inhibition might be a medically relevant avenue for the treatment of muscle wasting in heart failure.
Conclusion: Myostatin released from cardiomyocytes induces skeletal muscle wasting in heart failure. Targeted inhibition of myostatin in cardiac cachexia might be a therapeutic option in the future. 21
Regulatory T Cells Ameliorate Angiotensin II-Induced Cardiac Damage
Summary: Regulatory T (Treg) cells keep the immune system under control. When they are absent, fulminant autoimmunity may occur. Treg cells have been implicated in cardiovascular diseases, including atherosclerosis and diabetes mellitus. A therapeutic potential for Treg cells has been suggested in combating allograft rejection and autoimmune diseases. In earlier studies, we were impressed by the participation of immune responses in angiotensin II (Ang II)-mediated target organ damage. Innate and adaptive cellular and even antibody responses can be observed. Here, we test the notion that Treg cells would control inflammation in a mouse model involving sustained Ang II infusion. Control mice develop hypertension, cardiac hypertrophy, and easily evoked ventricular arrhythmias after catheter stimulation. The hearts exhibit immune cell infiltration, tumor necrosis factor-␣ expression, and fibrosis. We injected Treg cells obtained from spleens and lymph nodes of donor mice into mice that then received Ang II. Telemetric blood pressure measurements were the same. However, Treg-treated mice developed less cardiac hypertrophy, less tumor necrosis factor-␣ expression, and less immune cell infiltration and resisted stimulated arrhythmia. We found that Ang II did not directly influence Treg cells. However, Treg treatment maintained other T-cell populations closer to the proportion observed in control mice compared with mice given Ang II but no Treg cells. The importance of our findings is mechanistic. Our results underscore earlier observations on T lymphocytes, other immune cells, and their regulators in blood pressure responses and target organ damage after Ang II treatment. They suggest additional avenues of research relative to Ang II-related target organ damage and immunity.
Conclusion: Immunosuppressive effects of transferred Treg cells ameliorated cardiac damage and accounted for the improved electric remodeling independently of blood pressure-lowering effects. Our results provide new insights into the pathogenesis of hypertensive cardiac damage and could therefore lead to new therapeutic approaches that involve manipulation of the immune system. 22
Intracoronary Administration of Cardiac Progenitor Cells Alleviates Left Ventricular Dysfunction in Rats With a 30-Day-Old Infarction
Summary: Heart failure after myocardial infarction is one of the most prevalent causes of morbidity and mortality worldwide. Although pharmaceutical and interventional therapies have greatly ameliorated this problem, new more effective approaches are urgently needed. The discovery of resident cardiac progenitor cells (CPCs) in the adult mammalian heart has sparked hope for development of an "ideal" cell type for cardiac reparative/regenerative therapy. These resident CPCs have been shown to commit to a myocardial lineage and can be harvested from the heart and expanded in culture. Previous in vivo studies have shown that administration of CPCs to rats with acute myocardial infarction results in tissue regeneration and left ventricular functional improvement. We sought to extend these findings by determining whether intracoronary infusion of CPCs (the most clinically relevant strategy) can improve function in the setting of an old myocardial infarction (scar). We found that intracoronary infusion of CPCs into a scar produces beneficial structural and functional effects, and that although exogenous CPCs can differentiate into new cardiac cells, this mechanism is not sufficient to explain all of the observed benefits, which suggests paracrine effects. Infusion of exogenous CPCs activated endogenous CPCs, which suggests that this may be a major mechanism for the benefit. These data support the potential therapeutic utility of CPCs in patients with old myocardial infarction.
Conclusion: Intracoronary administration of CPCs in the setting of an old MI produces beneficial structural and functional effects. Although exogenous CPCs can differentiate into new cardiac cells, this mechanism is not sufficient to explain the benefits, which suggests paracrine effects; among these, the present data identify activation of endogenous CPCs. This is the first report that CPCs are beneficial in the setting of an old MI when given by intracoronary infusion, the most widely applicable therapeutic approach in patients. Furthermore, this is the first evidence that exogenous CPC administration activates endogenous CPCs. These results open the door to new therapeutic applications for the use of autologous CPCs in patients with old MI and chronic ischemic cardiomyopathy. 23
Increased Expression of Integrin-Linked Kinase Attenuates Left Ventricular Remodeling and Improves Cardiac Function After Myocardial Infarction
Summary: Postinfarction ventricular remodeling, consisting of changes in cardiac geometry and function, is an important cause of heart failure after myocardial infarction. Current clinical approaches to preventing this include early recanalization of the infarct-related artery and pharmacological interventions (for example, angiotensin converting-enzyme inhibition, ␤-blockade), but despite such approaches, progressive remodeling still occurs with resultant ventricular dysfunction. Integrin-linked kinase (ILK), a multifunctional protein kinase, has been reported to play important roles in regulating angiogenesis, cell proliferation, and survival and has also been shown to be crucial in the maintenance of cardiac structure and function in mice with cardiac-specific ILK ablation. However, to date, its role, if any, in postinfarction ventricular remodeling has not been shown. The present study indicates that overexpression of ILK by adenoviral gene transfer after myocardial infarction in rats attenuates cardiac remodeling and improves cardiac function. This is accompanied by enhanced neovascularization, reduced myocyte apoptosis, decreased fibrosis, and elevated cardiomyocyte proliferation. ILK also exhibits a rescue effect on the remodeling process after delayed delivery (1 week after myocardial infarction). Our findings suggest that interventions including gene therapy designed to increase ILK expression may be a promising therapeutic approach to prevent postinfarction ventricular remodeling and consequent heart failure.
Conclusion: ILK gene therapy improves cardiac remodeling and function in rats after myocardial infarction and is associated with increased angiogenesis, reduced apoptosis, and increased cardiomyocyte proliferation. This may represent a new approach to the treatment of postinfarct remodeling and subsequent heart failure. 24
Collagen-Targeting Vascular Endothelial Growth Factor Improves Cardiac Performance After Myocardial Infarction
Summary: Clinical trials of vascular endothelial growth factor (VEGF) gene therapy have proven that VEGF has beneficial effects on ischemic heart disease; however, potential problems associated with the prolonged and excessive production of VEGF cannot be ignored. Clinical studies of VEGF protein revealed evidence of a dose-dependent effect (ie, high-dose VEGF protein resulted in a better therapeutic effect). Given the side effects of high-level VEGF in the circulation, an increase in the local VEGF level may represent a reasonable treatment for ischemic heart disease. In the present study, we investigated the angiogenic effect of a fusion protein composed of VEGF and a collagen-binding domain (CBD-VEGF) and its therapeutic effects in a rat acute myocardial infarction model. The results demonstrated that CBD-VEGF induced much more blood vessel formation than native VEGF in collagen membranes implanted subcutaneously. Compared with native VEGF, CBD-VEGF maintained a higher level in extracellular matrix and a lower level in circulation, and it preserved heart function, reduced scar size, and increased capillary vessels after injection into the border zone of acute myocardial infarction in rats. Although the latent side effects and precise role of CBD-VEGF during healing must be investigated further, our results may suggest a novel therapeutic approach for patients with ischemic heart disease.
Conclusion:
The injection of CBD-VEGF improved cardiac function in rats with induced acute myocardial infarction. This could potentially provide a new treatment option for myocardial infarction. 25
Dehydroepiandrosterone Reverses Systemic Vascular Remodeling Through the Inhibition of the Akt/GSK3-␤/NFAT Axis
Summary: In response to injury, whether by an instrument during a percutaneous intervention or by inflammation, vascular smooth muscle cells proliferate excessively, leading to lumen obliteration. In coronary interventions, there has been some success in the prevention of restenosis by expensive therapies like drug-eluting stents. Systemic and nontoxic therapies to treat remodeled vessels or to prevent restenosis are not available. Here, we show that a naturally occurring steroid hormone (dehydroepiandrosterone [DHEA]), when used pharmacologically at high doses, can reverse established vascular remodeling in several in vitro and in vivo models in rats and human tissues. We show that DHEA has effects that are not mediated by the standard steroid receptors but rather via a membrane G protein-coupled receptor. DHEA can suppress the Akt axis, which, like in cancer cells, causes smooth muscle cell proliferation and resistance to apoptosis. As a result, DHEA in the drinking water reverses vascular remodeling without affecting normal vessels by inhibiting proliferation and inducing apoptosis within the vascular wall. The selectivity of DHEA to the diseased vessels, the fact that it has been used in pharmacological doses in humans with excellent toxicity profile, and its very low price (a generic drug) make it a very good candidate for clinical translation. Early-phase clinical trials need to determine whether DHEA can be used systematically at the time of vascular interventions (coronary or peripheral vessels) or locally (via a device or stent) to limit vascular remodeling.
Conclusion:
We suggest that the orally available DHEA might be an attractive candidate for the treatment of systemic vascular remodeling, including restenosis, and we propose a novel mechanism of action for this important hormone and drug. 26
Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy: Haploinsufficiency, Deranged Phosphorylation, and Cardiomyocyte Dysfunction
Summary: Familial hypertrophic cardiomyopathy is the most frequent inheritable cardiac disease, with a prevalence of 1/500. Mutations in the MYBPC3 gene encoding cardiac myosin-binding protein C (cMyBP-C) represent Ͼ40% of all familial hypertrophic cardiomyopathy cases. Cardiac MyBP-C is bound to the thick myosin filament and may influence binding of the myosin head to actin and thereby force generation and pressure development of the heart. cMyBP-C function is influenced by ␤-adrenergic stimulation through protein kinase A-mediated phosphorylation. Most MYBPC3 mutations are predicted to produce C-terminally truncated proteins, lacking titin and/or major myosin binding sites. Approximately 35% of the familial hypertrophic cardiomyopathy patients in the Netherlands have founder mutations in the MYBPC3 gene that encode C-terminally truncated proteins. This allowed us to investigate whether truncating mutations in MYBPC3 alter sarcomeric protein composition and function in a rather homogeneous patient group. No truncated cMyBP-C was detected, full-length cMyBP-C was reduced by 33% compared with nonfailing myocardium, and cMyBP-C phosphorylation was preserved. Our data therefore indicate that the pathomechanism involves haploinsufficiency rather than a poison polypeptide. Force measurements in single cardiomyocytes revealed reduced maximal force-generating capacity compared with healthy cells. In addition, Ca2ϩ sensitivity of the contractile apparatus was increased because of hypophosphorylation of troponin I, another target of protein kinase A. We conclude that the sarcomeric phenotype in familial hypertrophic cardiomyopathy with MYBPC3 mutations includes a primary contractile sarcomeric defect causing deranged secondary alterations in protein phosphorylation. Our data therefore suggest that contractile dysfunction is a pivotal link between the mutant sarcomeric protein and pathological hypertrophic cardiomyopathy.
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Conclusion: Frameshift MYBPC3 mutations cause haploinsufficiency, deranged phosphorylation of contractile proteins, and reduced maximal force-generating capacity of cardiomyocytes. The enhanced Ca2ϩ sensitivity in MYBPC3mut is due to hypophosphorylation of troponin I secondary to mutation-induced dysfunction. 27
Endothelial Progenitor Cells Bind and Inhibit Platelet Function and Thrombus Formation
Summary: Endothelial progenitor cells (EPCs) represent a promising therapeutic approach for the treatment of cardiovascular diseases. However, comprehensive delineation of the biology of these cells and the manner in which they interact with other blood and vascular cells is critical to fully understand their potential therapeutic properties. Herein, we addressed the interactions between EPCs and platelets and their impact on platelet function and thrombus formation, which may be relevant to the management of atherothrombosis during acute coronary syndromes and after percutaneous coronary interventions. We found that human peripheral blood monocytederived EPCs in culture bound platelets via CD62P and inhibited platelet activation, aggregation, and adhesion to collagen in vitro, mainly via upregulation of cyclooxygenase-2 and secretion of prostacyclin. Moreover, in a murine arterial thrombosis model, injection of EPCs led to their incorporation into sites of injury and impaired thrombus formation, leading to an incomplete occlusion. In addition to the well-documented roles of EPCs in angiogenesis and vascular repair, our findings highlight a new biological role for EPCs in regulating platelet function, which may, in turn, limit thrombogenesis while maintaining hemostasis at sites of vascular injury. These antiplatelet properties may ultimately lead to the development of novel EPC-derived antithrombotic therapies.
Conclusion: Peripheral blood mononuclear cell-derived EPCs bind platelets via CD62P and inhibit platelet activation, aggregation, adhesion to collagen, and thrombus formation, predominantly via upregulation of cyclooxygenase-2 and secretion of prostacyclin. These findings add new insights into the biology of EPCs and define their potential roles in regulating platelet function and thrombosis. 28
Diabetes Mellitus Activates Signal Transduction Pathways Resulting in Vascular Endothelial Growth Factor Resistance of Human Monocytes
Summary: This article describes a functionally relevant molecular defect in monocytes from individuals with diabetes mellitus (DM). It is well established that monocytes play a crucial role in both arteriogenesis (ie, collateral growth) and atherogenesis. Moreover, there is evidence that DM-related monocyte dysfunction such as impaired monocyte chemotaxis toward vascular endothelial growth factor-A (VEGF) is associated with impaired collateral growth and accelerated atherogenesis. We now report that the functional monocyte defect in DM is based on VEGF resistance: Although VEGF can activate its specific receptor, the migratory response is blocked. On a molecular level, this blockade/resistance can be explained by activation of crucial VEGF signaling pathways, including the Akt and mitogen-activated protein kinase pathways. DM is associated with reduced activity of protein tyrosine phosphatases, which allows enhanced activation of related kinases and results in nonspecific preactivation of relevant signaling pathways. In fact, we can mimic this diabetic phenotype by experimental inhibition of protein tyrosine phosphatases, again resulting in preactivation of signaling molecules and impaired chemotaxis. Likewise, receptor for advanced glycation end products activation, also known to occur in DM, results in similar changes associated with VEGF resistance. The clinical perspective of this concept is to use VEGF resistance and its underlying molecular changes for diagnostic purposes and thereby predict the efficiency of VEGF action in cardiovascular repair and potentially in therapeutic angiogenesis. Moreover, the therapeutic prevention of VEGF resistance could represent a novel concept to attenuate the negative functional consequences of DM in the vasculature.
Conclusion:
We propose that elevated advanced glycation end products expression and increased oxidative stress in diabetic monocytes lead to activation of VEGFR-1-related signaling pathways and to desensitization of VEGFR-1 responses. These data establish VEGF resistance as a novel molecular concept for DM-related cellular dysfunction. 29
Mechanism of Improved Cardiac Function After Bone Marrow Mononuclear Cell Therapy: Role of Cardiovascular Lineage Commitment
Summary: Cell therapy with bone marrow-derived mononuclear cells is a promising option to improve functional recovery after acute myocardial infarction; however, the mechanism underlying the functional improvement of cell therapy is unclear. Here, we demonstrate that selective depletion of vascular-committed cells that express endothelial nitric oxide synthase results in deterioration of cardiac function and a reduction of capillary density, which indicates that vascular-committed cells contribute to the beneficial effects of injected bone marrow-derived mononuclear cells.
Conclusion: This study demonstrates that elimination of bone marrow mononuclear cells reexpressing endothelial nitric oxide synthase particularly induced a deterioration of cardiac function, which indicates a functional contribution of the vascular cell fate decision of human bone marrow-derived mononuclear cells in vivo. 30

Cardiomyogenic Potential of C-Kit؉-Expressing Cells Derived From Neonatal and Adult Mouse Hearts
Summary: In recent years, intracoronary cell delivery of stem/ progenitor cells has emerged as a potential therapy to restore impaired cardiac function. However, the efficacy of this treatment in improving ejection fraction has been moderate at best. The quest for a more potent stem/progenitor cell has identified cardiac-resident c-kitϩ cells as a potential candidate. During embryonic heart development, primitive Nkx2.5ϩ/c-kitϩ/Flk1ϩ cardiac progenitor cells have been shown to undergo cardiomyogenic differentiation. However, the role of c-kitϩ cell populations in the adult heart is less clear. The study by Zaruba and colleagues utilized reporter transgenes in conjunction with in vitro and in vivo assays to monitor the survival and differentiation of cardiac-resident c-kitϩ cell populations isolated from different stages of postnatal development. The data suggest that the neonatal heart harbors a resident c-kitϩ cell population with cardiomyogenic potential. However, this activity is greatly reduced in the adult heart, suggesting that the cardiomyogenic activity is subject to temporal limitations or, alternatively, that the cardiomyogenic subpopulation is largely absent in the adult heart. Uncovering the molecular basis for these limitations may permit robust cardiomyogenic induction in adult-derived cardiac c-kitϩ cells. With respect to clinical trials utilizing endogenous c-kitϩ stem cell populations, this report underscores the importance of determining the extent to which secondary effects such as enhanced neoangiogenesis or inhibition of cardiomyocyte apoptosis contribute to functional improvement.
Conclusion: These data suggest that the ability of cardiac-resident c-kitϩ cells to acquire a cardiomyogenic phenotype is subject to temporal limitations or, alternatively, that the cardiomyogenic population is lost. Elucidation of the underlying molecular basis may permit robust cardiomyogenic induction in adult-derived cardiac c-kitϩ cells. 31
MicroRNA-494 Targeting Both Proapoptotic and Antiapoptotic Proteins Protects Against Ischemia/Reperfusion-Induced Cardiac Injury
Summary: MicroRNAs (miRs), a new class of non-protein-coding small RNAs, have emerged as regulators that control the expression e934 Circulation December 20/27, 2011 of hundreds of proteins. As a consequence, they may widely influence the signaling networks leading to pathological or physiological responses such as myocardial ischemia/reperfusion-induced injury and ischemia preconditioning-elicited cardioprotection. Although miR expression has been profiled in infarcted hearts from animal models and human patients, the role of a specific miR in ischemic heart disease is just emerging. Uncovering miRs as important regulators not only for single genes but also for whole gene networks has enormous therapeutic implications. In the present study, we discovered that increased levels of mature miR-494 rendered cardioprotection against ischemia/reperfusioninduced injury, whereas knockdown of endogenous miR-494 by administration of antagomiR-494 sensitized hearts to ischemia/reperfusion injury. Importantly, we identified that miR-494 -targeted PTEN, ROCK1, and CAMKII␦ in cardiomyocytes consequently activated the Akt signaling pathway. These data suggest that the downregulation of miR-494 observed in human failing hearts may be causally involved in the progression of heart failure, at least in part. Therefore, systemic or local administration of miR-494 may be the newest prospect for the management of ischemic heart disease.
Conclusion: Our findings suggest that although miR-494 targets both proapoptotic and antiapoptotic proteins, the ultimate consequence is activation of the Akt pathway, leading to cardioprotective effects against ischemia/reperfusion-induced injury. Thus, miR-494 may constitute a new therapeutic agent for the treatment of ischemic heart disease. 32
Critical Role of Transcription Factor cAMP Response Element Modulator in ␤1-Adrenoceptor-Mediated Cardiac Dysfunction
Summary: Heart failure, the common end stage of various cardiac diseases, is defined as the inability of the heart to cover the body's blood supply and is associated with a poor prognosis. Supported by clinical studies and studies on various animal models, chronic stimulation of the ␤1-adrenoceptor (␤1AR) by elevated plasma catecholamines is regarded as a central pathogenetic factor of human heart failure, leading to the progression of the disease. Transcription factors of the cAMP response element binding protein/cAMP response element modulator (CREM) family mediate a cAMP-dependent control of gene expression and may therefore contribute to ␤1AR-mediated detrimental cardiac effects. In the present study, we show that the inactivation of CREM protects from cardiomyocyte hypertrophy, fibrosis, and left ventricular dysfunction in mice with heart-directed expression of the ␤1AR, along with the altered expression of various myocardial proteins including the cardiac ryanodine receptor, tropomyosin 1a, and cardiac a-actin. These findings support the notion that the regulation of genes by CREM represents an important mechanism of ␤1AR-induced cardiac damage and suggest the inhibition of CREM as a promising therapeutic option for treating heart failure.
Conclusion:
The results imply the regulation of genes by CREM as an important mechanism of ␤1AR-induced cardiac damage in mice. 33
Mobilized Human Hematopoietic Stem/Progenitor Cells Promote Kidney Repair After Ischemia/Reperfusion Injury
Summary: Acute kidney injury, formerly known as acute tubular necrosis, has reached epidemic proportions. It is a harbinger for chronic kidney disease, end-stage kidney disease, cardiovascular events, and untimely death. Despite this, other than supportive management, there are no active therapeutic strategies that promote repair and regeneration. In this article, Li and colleagues identify a promising new strategy for the treatment of acute kidney injury using cellular therapy. Human stem cells were mobilized from healthy donors and purified from peripheral blood. They were infused into mice with acute kidney injury. The human stem cells trafficked to the kidney, where they orchestrated microvascular repair. The consequence of this microvascular repair was enhanced animal survival and prompt resolution of organ failure. One month after injury, the propensity to develop organ fibrosis, a characteristic of chronic kidney disease, was significantly diminished. The kidney repair prompted by human stem cells manifested as enhanced proliferation in both the microvascular and nephron compartments of the injured organ rather than replacement of kidney cells. These compelling studies in mice highlight the urgent need for new therapies focused on vascular repair/regeneration and raise the possibility that donor human stem cells might be indicated prophylactically in patients at high risk of acute kidney injury.
Conclusion: These studies advance human hematopoietic stem/ progenitor cells as a promising therapeutic strategy for promoting renal repair after injury. 34
Prelamin A Acts to Accelerate Smooth Muscle Cell Senescence and Is a Novel Biomarker of Human Vascular Aging
Summary: Age is the strongest risk factor for the development of vascular decline and associated mortality. Therefore, understanding the mechanisms of cell-specific forms of aging may lead to the development of novel targets for therapeutic intervention. Children with the genetic condition Hutchison-Gilford progeria syndrome develop tissue-specific symptoms of premature aging and die of myocardial infarction within the second decade. This is due to rapid vascular decline caused by the severe loss and dysfunction of vascular smooth muscle cells (VSMCs). Hutchison-Gilford progeria syndrome is caused by the toxic accumulation of a mutant form of the nuclear lamina protein lamin A. This mutant protein, called progerin, acts to deregulate mitosis and DNA damage signaling, leading to premature cell death and senescence. In this study, we show that VSMC aging and disease in the normal population are associated with the abnormal accumulation of prelamin A, which, like progerin, is an unprocessed form of lamin A. In normal aging, the accumulation of prelamin A is caused in part by the downregulation of the processing enzyme FACE1 by oxidative stress. Prelamin A accumulation accelerates VSMC DNA damage and senescence and may also impinge on VSMC phenotype to promote age-associated vascular pathologies such as calcification. Importantly, some of the toxic effects of prelamin A are thought to be due to permanent farnesylation, suggesting that drugs that interfere with this pathway, such as statins, may be useful for the treatment of age-related vascular dysfunction.
Conclusion: This study shows that prelamin A is a novel biomarker of VSMC aging and disease that acts to accelerate senescence. It therefore represents a novel target to ameliorate the effects of age-induced vascular dysfunction. 35
Oral Anti-CD3 Antibody Treatment Induces Regulatory T Cells and Inhibits the Development of Atherosclerosis in Mice
Summary: Atherosclerosis is a chronic inflammatory condition of the arterial wall involving immune cells and their releasing molecules. This important notion has led to a quest to develop an anti-inflammatory and immune therapy for prevention of atherosclerosis in clinical patients. Accumulating evidence suggests that several subsets of regulatory T cells (Tregs) inhibit atherosclerosis development through the downregulation of activated T-cell responses. Recent studies have demonstrated that parenteral administration of anti-CD3-specific antibody restores long-lasting selftolerance and is effective in autoimmune diabetes in mice and humans, partly because of the expansion of CD4ϩCD25ϩ Tregs. Interestingly, orally administered anti-CD3 antibody has been shown
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to prevent systemic autoimmunity through induction of novel Tregs expressing latency-associated peptide (LAP) on their surface in the gut. In the present study, we first show that oral anti-CD3 antibody treatment attenuates atherosclerotic lesion formation and plaque inflammation and that this suppression is associated with an increase in the number of CD4ϩCD25-LAPϩ Tregs and, unexpectedly, CD4ϩCD25ϩFoxp3ϩ Tregs, which are possibly induced in the gut-associated lymphoid tissue and migrate into other lymphoid organs or atherosclerotic plaques, subsequently leading to suppression of T-helper type 1 and type 2 immune responses through a transforming growth factor-␤-dependent mechanism. Our data indicate that oral administration of anti-CD3 antibody seems to be safe and easy to apply and therefore could be used as a promising therapeutic approach for atherosclerotic vascular disorders. Clinical studies are required.
Conclusion:
Our findings indicate the atheroprotective role of oral anti-CD3 antibody treatment in mice via induction of a regulatory T-cell response. These findings suggest that oral immune modulation may represent an attractive therapeutic approach to atherosclerosis. 36
Immunoglobulin M Is Required for Protection Against Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice
Summary: Previous immunization experiments in animals and clinical association studies have suggested that IgM antibodies may have protective effects against the development of atherosclerosis. In this study, we have addressed the role of IgM in atherogenesis by crossing the low-density lipoprotein (LDL) receptor-deficient (LdlrϪ/Ϫ) mouse model of atherosclerosis with mice that have no IgM in their serum as a result of defective release of IgM from B lymphocytes (sIgMϪ/Ϫ). sIgM.LdlrϪ/Ϫ mice showed marked acceleration of atherosclerosis compared with LdlrϪ/Ϫ mice with larger lesions, early lesional cholesterol crystal formation, and an increase in vascular smooth muscle cell content consistent with fibrous cap formation. Although IgM is a potent activator of complement and thus has an important function in disposing of apoptotic cells, atheroprotection by IgM, in part, is not mediated through complement activation and consequently is at least partially independent of apoptotic cell clearance. Overall, our data provide the first direct evidence that endogenous IgM natural antibodies are necessary for arterial homeostasis and corroborate clinical studies that have observed an inverse correlation between IgM anti-oxidized LDL antibodies and progression of carotid atherosclerosis or angiographically determined coronary artery disease. This work lends support for developing immunization strategies to boost natural antibody protection and potentially limit atherosclerosis.
Conclusion:
This study provides direct evidence that IgM antibodies play a central role in protection against atherosclerosis. The mechanism appears to be at least partly independent of classical pathway complement activation by C1q. 37
Microarray Identifies Extensive Downregulation of Noncollagen Extracellular Matrix and Profibrotic Growth Factor Genes in Chronic Isolated Mitral Regurgitation in the Dog
Summary: Evidence from the dog model of isolated mitral regurgitation suggests that persistent loss of interstitial collagen is central to chronic eccentric left ventricular and cardiomyocyte remodeling, but the molecular basis remains unclear. The findings of the current investigation demonstrating a decrease in molecular signals that decrease synthesis of matrix in the face of increased matrix degradation could explain why antifibrotic drugs such as angiotensinconverting enzyme inhibitors and angiotensin II type 1 receptor blockers do not attenuate left ventricular dilatation and matrix loss in the canine model of isolated mitral regurgitation and in some limited patient studies. This animal model is especially relevant because there is currently no recommended medical therapy available to attenuate left ventricular remodeling and thereby delay the need for valve surgery in patients with isolated mitral regurgitation. These findings may call for a new treatment paradigm that addresses matrix loss to attenuate progressive left ventricular dilatation in isolated mitral regurgitation.
Conclusion: Left ventricular collagen loss in isolated, compensated mitral regurgitation is chiefly due to posttranslational processing and degradation. The downregulation of multiple noncollagen genes important in global extracellular matrix structure, coupled with decreased expression of multiple profibrotic factors, explains the failure to replace interstitial collagen in the MR heart. 38
AMP-Activated Protein Kinase Deficiency Enhances Myocardial Ischemia/Reperfusion Injury but Has Minimal Effect on the Antioxidant/Antinitrative Protection of Adiponectin
Summary: The incidence of obesity and type 2 diabetes mellitus is increasing worldwide, and both of these conditions increase the risk of cardiovascular disease. Adiponectin is an adipocyte-specific protein that plays a critical role in glucose and lipid metabolism regulation. Prospective studies have demonstrated the association between decreased plasma adiponectin levels and increased cardiovascular morbidity in diabetic patients. Clarification of the mechanisms by which adiponectin acts advantageously may contribute to our understanding of diabetic pathophysiology and provide insight to a potential therapeutic modality. Considerable evidence exists that the metabolic regulatory, anti-inflammatory, and vascular protective effects of adiponectin are largely mediated by activation of AMPactivated protein kinase (AMPK). However, our present study demonstrated for the first time that the antiischemic and cardioprotective effect of adiponectin is largely AMPK independent. In recent years, AMPK has become a major target in the search for effective treatments for metabolic syndromes, including type II diabetes. However, our present experimental results strongly suggest that adiponectin might be a better, more effective therapeutic target in the treatment of ischemic heart injury in diabetic patients. For instance, administration of adiponectin may still be an effective therapy under conditions in which the AMPK signaling-dependent cardioprotective agents become ineffective. Moreover, our present experimental results demonstrated that administration of globular domain of adiponectin reduced synchronized nitric oxide/superoxide overproduction from NADPH oxidase and inducible nitric oxide synthase and effectively blocked peroxynitrite formation in ischemic/reperfused hearts. As such, interventions with aims of bolstering adiponectin production may hold great potential in reducing diabetic patient mortality in those with ischemic heart disease.
Conclusion:
Collectively, our results demonstrated that AMPK deficiency significantly increases myocardial ischemia/reperfusion injury in vivo but has minimal effect on the antioxidative/antinitrative protection of adiponectin. 39
Smooth Muscle Notch1 Mediates Neointimal Formation After Vascular Injury
Summary: The signaling mechanisms that govern the response of smooth muscle after vascular injury and during neointimal formation are not known. The Notch receptors are highly conserved membranebound receptors that regulate binary cell fate determination and embryonic development. However, their role in postnatal vascular remodeling is not well understood. In this study, we showed that after carotid artery ligation, Notch1 was highly expressed in neointimal smooth muscle cells (SMCs), whereas Notch2 and Notch3 were constitutively expressed in medial and neointimal SMCs. These different patterns of expression suggest that Notch1, Notch2, and
Notch3 may have distinct roles in SMC function. Mutant mice with targeted deletion of Notch1, but not Notch3, in SMCs exhibited decreased neointimal formation after carotid artery ligation. Indeed, compared with wild-type mice, activated Notch signaling was substantially reduced after carotid artery ligation in global and SMC-specific Notch1 hemizygous knockout mice. This was associated with decreased SMC chemotaxis and proliferation and increased apoptosis. In SMCs derived from CHF1/Hey2 knockout mice, activation of Notch signaling did not lead to increased SMC proliferation or migration. These findings indicate that Notch1 mediates SMC proliferation and neointimal formation after vascular injury through CHF1/Hey2 and suggest that therapies that target Notch1/CHF1/Hey2 in SMCs may be beneficial in preventing vascular proliferative diseases.
Conclusion:
These findings indicate that Notch1, rather than Notch3, mediates SMC proliferation and neointimal formation after vascular injury through CHF1/Hey2 and suggest that therapies that target Notch1/CHF1/Hey2 in SMCs may be beneficial in preventing vascular proliferative diseases. 40
Pharmacological Activation of Soluble Guanylate Cyclase Protects the Heart Against Ischemic Injury
Summary: Although clinical care is improved, public awareness is raised, and health innovations are widely used, myocardial infarction remains the leading cause of death worldwide. The nitric oxide/ soluble guanylate cyclase/cGMP/cGMP-dependent protein kinase G signaling cascade has been shown to be an important sequence in both preconditioning and postconditioning. Alteration of this pathway has been thought to be involved in the pathogenesis of various cardiovascular diseases and is subject to the development of new therapeutic agents. Cinaciguat, the novel nitric oxide-and hemeindependent activator of soluble guanylate cyclase, is currently being evaluated for the treatment of chronic heart failure in early clinical trials and appears to be well tolerated. Its nitric oxide independence may make it an ideal candidate for a pharmacological approach in acute myocardial infarction. In this study, we demonstrate that in a rat model of myocardial infarction induced by isoproterenol, cinaciguat treatment improves histopathologic lesions, improves cardiac performance, improves impaired cardiac relaxation, reduces oxidative stress, and ameliorates intracellular enzyme release. Furthermore, we demonstrate cardioprotective effect of postischemic cinaciguat treatment in a clinically relevant canine model of global cardiac ischemia/reperfusion injury. Collectively, these findings make cinaciguat a candidate for the prevention and treatment of acute myocardial ischemia in humans.
Conclusion: Pharmacological soluble guanylate cyclase activation could be a novel approach for the prevention and treatment of ischemic heart disease. 41
Endothelial Progenitor Cells Restore Renal Function in Chronic Experimental Renovascular Disease
Summary: Significant attention has been directed to the biological and therapeutic capabilities of progenitor cells. Endothelial progenitor cells mobilized endogenously in response to ischemia play a crucial role in augmenting neovascularization of ischemic tissues and repair of the vessel wall after endothelial cell denudation. A large body of experimental and clinical evidence accumulated over the last 10 years demonstrating that administration of endothelial progenitor cells could improve the function of the ischemic tissues. The present study tested the feasibility of using progenitor cells to treat the obstructed kidney in a model of chronic renovascular disease. This disease is difficult to treat and may induce hypertension and renal injury, leading to end-stage renal disease. In this model, a single intrarenal administration of endothelial progenitor cells restored renal hemodynamics and function, preserved renal microvascular architecture, and attenuated fibrosis of the ischemic kidney. The demonstrated capability of endothelial progenitor cells to restore vascular integrity and preserve the stenotic kidney may constitute an important step for designing novel therapeutic measures for management of patients with renovascular disease.
Conclusion: The present study shows that a single intrarenal infusion of autologous endothelial progenitor cells (EPCs) preserved microvascular architecture and function and decreased microvascular remodeling in experimental chronic renal artery stenosis (RAS). It is likely that restoration of the angiogenic cascade by autologous EPCs involved not only generation of new vessels but also acceleration of their maturation and stabilization. This contributed to preserving the blood supply, hemodynamics, and function of the RAS kidney, supporting EPCs as a promising therapeutic intervention for preserving the kidney in renovascular disease. 42
Notch Signaling Regulates Endothelial Progenitor Cell Activity During Recovery From Arterial Injury in Hypercholesterolemic Mice
Summary: Abundant evidence has linked hypercholesterolemia with the advent and progression of atherosclerosis. To facilitate the study of the mechanisms by which hypercholesterolemia leads to atherosclerosis, animal models have been developed. Most notably, the apolipoprotein E (ApoE)-null and low-density lipoprotein receptornull mice have been used extensively in attempts to gain a better understanding of the effects of high lipid levels on atheroma formation. In recent years, traditional cardiovascular risk factors have also been associated with decreased numbers of circulating endothelial progenitor cells (EPCs), which have been suggested to participate in endothelial repair and maintenance. Ample experimental evidence suggests that EPCs are mobilized from the bone marrow to the peripheral circulation after arterial injury (eg, percutaneous transluminal coronary angioplasty or stent implantation) and promote reendothelialization at the injury site, thereby speeding endothelial recovery and reducing the risk of restenosis and atherosclerotic plaque formation. Here, we compared EPC recruitment, reendothelialization, and plaque formation after carotid artery injury in wild-type mice and ApoEϪ/Ϫ mice. Our findings indicate that EPC recruitment was higher in ApoEϪ/Ϫ mice than in wild-type mice and that the enhanced recruitment likely evolves through a moderate decline in Notch expression. Reendothelialization was also greater in ApoEϪ/Ϫ mice, which was somewhat surprising because ApoEϪ/Ϫ mice are prone to atherosclerosis. Furthermore, transplanted, bone-marrow-derived EPCs were found at the border of the atherosclerotic lesions, which could suggest that EPCs contribute to the early stage of plaque formation. However, the clinical implications of these observations must be interpreted with caution, particularly because circulating EPC levels were higher in ApoEϪ/Ϫ mice than in wild-type mice, whereas hypercholesterolemia, hypertension, and many other risk factors for cardiovascular disease are associated with declines in human EPC levels. Collectively, our findings emphasize the need for additional experiments in other hypercholesterolemic animal models and underscore the potential for genetic mouse models of human disease to yield data that do not necessarily reflect clinical reality. To clarify the paradoxical observation on the direct effect of cholesterol on EPC contribution to reendothelialization versus plaque formation in Apo E knockout mice after arterial injury, further investigations using different types of hypercholesterolemic animals and, importantly, additional clinical correlation are required.
Conclusion:
The results presented here provide novel insights into the role of EPCs during atherosclerosis and suggest that cholesterol and Notch1 may be involved in the regulation of EPC activity. 43 The Editors Most Read in Molecular Cardiology e937
Modulation of Calcium-Activated Potassium Channels Induces Cardiogenesis of Pluripotent Stem Cells and Enrichment of Pacemaker-Like Cells
Summary: It is well accepted that embryonic stem cells represent a particularly attractive source for ex vivo generation of cardiomyocytes. Considering the feasibility of in vitro model systems for pharmacological screenings, toxicological, or even potential cell therapeutic applications, major obstacles need to be overcome. Pharmaceutical model systems require a (1) high purity of the cell system; (2) specifically, differentiated cell subtypes, such as cardiac pacemaker like cells; and (3) absence of unphysiological alterations due to genetically engineered cell genomes. Relative to the future potential for cell therapeutic applications, furthermore, in vivo improvement of (1) contractile heart function, (2) prevention of arrhythmias caused by insufficient graft guidance, (3) potential teratoma formation, and (4) immunotolerance are the crucial premises. The differentiation system presented here provides an interesting tool for applications in biomedical engineering, pathophysiological, and toxicological studies and even potential therapeutic applications. Here we provide a new cardiac differentiation system exclusive of genetic manipulation and lineage selection and thus fulfilling most of these criteria.
Conclusion: Small and intermediate conductance activation drives the fate of pluripotent cells toward mesoderm commitment and cardiomyocyte specification, preferentially into nodal-like cardiomyocytes. This provides a novel strategy for the enrichment of cardiomyocytes and in particular, the generation of a specific subtype of cardiomyocytes, pacemaker-like cells, without genetic modification. 44
Neuropilin-1 Identifies Endothelial Precursors in Human and Murine Embryonic Stem Cells Before CD34 Expression
Summary: Our understanding of the manner in which endothelial cells develop from embryonic stem cells is still incomplete. An important question is whether endothelial precursor cells have common identifying features that serve as "biomarkers" for tracking their development into mature endothelial cells. Here we report that expressions of 3 markers-(1) neuropilin-1 (a vascular endothelial growth factor coreceptor); (2) Brachyury; and (3) vascular endothelial growth factor receptor 2-identify human and mouse embryonic stem cells that developmentally become endothelial cells. Neuropilin-1 expression occurs very early and defines the origin of a single population of human and mouse stem cells that progress toward endothelial cells. Use of these biomarkers may facilitate marking and tracking of embryonic stem cells that may eventually be used for therapeutic purposes.
Conclusion:
The onset of Neuropilin-1 (NRP-1) expression identifies endothelial precursors in murine and human stem cells. The findings define the origin of a single population of endothelial precursors from human and murine stem cells to endothelial cells. Additionally, the function of both the VEGF and Semaphorin binding activities of NRP-1 has important roles in the differentiation of stem cells to endothelial cells, providing novel insights into the role of NRP-1 in a model of vasculogenesis. 45
MG53 Constitutes a Primary Determinant of Cardiac Ischemic Preconditioning
Summary: Cardiac ischemia is the current leading cause of death in the Western world. Because of the limited regenerative capacity of cardiomyocytes, ameliorating ischemia-induced myocardial damage is an important therapeutic target in the treatment of ischemic heart disease. The deleterious effects of cardiac ischemia are ameliorated by ischemic preconditioning (IPC), in which transient ischemia protects against subsequent severe ischemia/reperfusion. In the present study, we have identified MG53, a muscle-specific tripartite motif family protein (TRIM72), as a primary component of cardiac IPC response. MG53-mediated cardioprotection is, at least in part, independent of its known function in membrane repair because IPC profoundly suppresses apoptotic events, which do not involve breakdown of the sarcolemmal membrane, in an MG53-dependent manner. Because IPC is a powerful intrinsic mechanism against ischemia/reperfusion-induced myocardial damage, the identification of MG53 as a primary component of the cardiac IPC response opens a promising therapeutic avenue for the treatment of ischemic heart disease. To translate our bench discoveries from rodents into clinical medicine, many important issues need to be addressed, including determining the potential role MG53 in ischemic postconditioning, in which brief episodes of ischemia/reperfusion applied at the onset of reperfusion confer cardioprotection, in mammalian species including rodents, large animals, and humans. Relative to IPC, ischemic postconditioning is clinically more attractive because of its therapeutic application at the predictable onset of reperfusion. Because MG53 is a muscle-specific TRIM protein, an intriguing question is whether other members of the TRIM family contribute to organ protection, particularly in organs in which an IPC response can be observed.
Conclusion: These results establish MG53 as a primary component of the cardiac IPC response, thus identifying a potentially important novel therapeutic target for the treatment of ischemic heart disease. 46
Survival and Cardiac Remodeling After Myocardial Infarction Are Critically Dependent on the Host Innate Immune Interleukin-1 Receptor-Associated Kinase-4 Signaling: A Regulator of Bone Marrow-Derived Dendritic Cells
Summary: Cardiac remodeling after myocardial infarction is a major substrate for the development of heart failure. A significant component of this remodeling is orchestrated by the inflammatory response of the host. Innate immunity is the first-line defense mechanism of the host against external injury, triggering pathways involved in Toll/interleukin-1 receptor signaling. We found that interleukin-1 receptor-associated kinase (IRAK-4), a major regulator of innate immune response, has a surprising but essential role in modulating the post-myocardial infarction remodeling process through the functional regulation of dendritic cells. Targeted removal of IRAK-4 led to major benefits in survival and cardiac remodeling after infarction. This was accompanied by decreased bone marrow dendritic cell mobilization and impaired maturation. However, transfer of adult mature dendritic cells, after infarction was completed, annulled this protective benefit. Thus, the Toll/IRAK-4 -dendritic cell axis has a detrimental effect on cardiac remodeling and may constitute a hitherto unrecognized new therapeutic target after infarction.
Conclusion: Deletion of IRAK-4 has favorable effects on survival and left ventricular remodeling after myocardial infarction through modification of the host inflammatory process by blunting the detrimental bone marrow dendritic cells mobilization after myocardial ischemia. 47
Transgenic Overexpression of Aldehyde Dehydrogenase-2 Rescues Chronic Alcohol Intake-Induced Myocardial Hypertrophy and Contractile Dysfunction
Summary: Almost 1 of every 3 alcoholics displays some degree of heart problems, collectively known as alcoholic cardiomyopathy. The present study shows that the ALDH2 enzyme is capable of mitigating cardiac remodeling and myocardial dysfunction after e938 Circulation December 20/27, 2011 chronic alcohol ingestion, possibly through facilitated acetaldehyde detoxification. Blood acetaldehyde levels are Ϸ10-fold higher in humans with defective ALDH2 (eg, Asians and blacks) than in normal individuals after alcohol ingestion. Allelic variation of ALDH genes, especially ALDH2 due to a point mutation in the active ALDH2*1 gene, significantly alters vulnerability for alcoholism and alcoholic complications; however, the jury is still out as to whether elevated acetaldehyde levels are directly involved in the origin of alcoholic cardiomyopathy or are simply the result of alcohol metabolism. The present study, which used transgenic mice with overexpression of ALDH2, provides the first evidence that facilitated acetaldehyde detoxification alone is sufficient to reverse the cardiac remodeling processes that lead to alcoholic cardiomyopathy. Results obtained in the present study support the conclusion that elevated acetaldehyde levels participate in cardiac remodeling and contractile defects, perhaps through NADPH oxidase-mediated oxidative stress and activation of hypertrophic signaling molecules. These data indicated that ALDH2 may be cardioprotective and counteract cardiac remodeling and myocardial dysfunction after chronic alcohol intake, thus providing its therapeutic potential in alcoholic and other forms of myocardial damage. Because convincing human case studies on the interaction between the ALDH2 gene polymorphism and heart function after chronic alcohol intake are lacking, caution must be exercised when evaluating the role of acetaldehyde and ALDH2 in the pathogenesis and management of alcoholic cardiomyopathy.
Conclusion:
The present results suggest that transgenic overexpression of ALDH2 effectively antagonizes chronic alcohol intakeelicited myocardial hypertrophy and contractile defect through a mechanism that is associated, at least in part, with phosphorylation of ASK-1, GSK-3␤, GATA4, and CREB. These data strongly support the notion that acetaldehyde may be an essential contributor to the chronic development of alcoholic cardiomyopathy. 48
Interferon-␥ and the Interferon-Inducible Chemokine CXCL10 Protect Against Aneurysm Formation and Rupture
Summary: A wealth of recent findings suggest that inflammation contributes to vascular disease; however, our understanding of the precise mechanisms involved remains incomplete. The present study defines a novel pathway in which 2 related inflammatory mediators, interferon-␥ and CXCL10, contribute to plaque formation in arteries but protect against the formation of vessel aneurysms. Thus, efforts to develop anti-inflammatory strategies for atherosclerosis must carefully consider potential effects on all types of vascular disease manifestations and must consider both the salutary and harmful aspects of the immune system.
Conclusion:
The present study defines a novel pathway in which interferon-␥ and its effector, CXCL10, contribute to divergent pathways in abdominal aortic aneurysm versus plaque formation, inhibiting the former pathology but promoting the latter. Thus, efforts to develop anti-inflammatory strategies for atherosclerosis must carefully consider potential effects on all manifestations of vascular disease. 49
Critical Role of Mast Cell Chymase in Mouse Abdominal Aortic Aneurysm Formation
Summary: Mast cells, the primary players in allergic immune responses, have also been implicated in the pathogenesis of many nonallergic human diseases, such as cancer, rheumatoid arthritis, and multiple sclerosis. We have recently shown that these inflammatory cells play detrimental roles in the pathogenesis of both atherosclerosis and abdominal aortic aneurysm (AAA). In mice, absence or inactivation of mast cells prevents the progression of these common vascular diseases, providing the novel concept of controlling these diseases with the use of currently available generic mast cell stabilizers in humans. Mechanistic analysis demonstrated that mast cells release proinflammatory cytokines to induce the expression and secretion of atherosclerosis-and AAA-pertinent cysteine protease cathepsins from vascular smooth muscle cells and endothelial cells. Such cysteinyl cathepsins have been suggested to participate directly in these vascular diseases mainly through their elastase and collagenase activities. Like macrophages, mast cells have reservoirs of proteases. Besides common cysteinyl cathepsins and matrix metalloproteinases, mast cells have the unique serine proteases tryptase and chymase. In this study, we proved the direct involvement of chymase in aortic elastase perfusion-induced mouse AAA. Mast cell chymases have been suggested to participate in vascular remodeling by activating matrix metalloproteinases and generating angiotensin II, critical molecules in the pathogenesis of atherosclerosis and AAA. In addition to these known pathological roles, we demonstrated in this study that mast cell chymases also control cysteinyl cathepsin expression and activation, neovascularization, and aortic smooth muscle cell apoptosis. Reduced AAA formation from mice lacking mast cell chymase and restoration of such reductions with reconstitution of mast cells from wild-type mice but not those of chymasedeficient mice strongly support a direct participation of mast cell chymases in mouse AAA formation. Observations of the AAA inhibitory effects of synthetic small-molecule orally active chymase inhibitor 
Erythropoietin Suppresses the Formation of Macrophage Foam Cells: Role of Liver X Receptor ␣
Summary: Atherosclerosis is a major cause of death resulting from cardiovascular diseases. Atherogenesis starts with an increase in circulating cholesterol levels and subsequently involves a complex cascade of events, including lipid modification, foam cell formation, and recurrent inflammation within the artery wall. Currently, the most widely prescribed medications for treating atherosclerosis are statins, a group of drugs that mainly aim to lower circulating cholesterol levels. Although clinical trials have favorably shown a reduction in atherogenic events by statins, this therapeutic strategy is not optimal. Foam cells derived from macrophages play a critical role in the initiation and progression of atherosclerosis. They not only accumulate lipids but also release inflammatory and chemotactic cytokines as atherogenic factors. Thus, therapeutic approaches for reducing form cell formation may also represent an important strategy for the prevention and treatment of atherosclerosis. Erythropoietin is known as a glycoprotein hormone that controls erythropoiesis. Erythropoietin has been used as a therapeutic agent to treat anemia in patients with chronic kidney disease or cancer. Although interest in other beneficial functions of erythropoietin has recently emerged, its role in atherogenesis is unknown. This study demonstrates that erythropoietin is increased mainly in the macrophage foam cells present in atherosclerotic lesions. Either treatment with exogenous erythropoietin or overexpression of erythropoietin markedly reduces foam cell formation by increasing the cholesterol efflux from macrophages, suggesting a novel antiatherogenic function of erythropoietin. Our findings may shed new light on the potential therapeutic application of erythropoietin to treat atherosclerosis.
Conclusion: Our data suggest that erythropoietin suppresses foam cell formation via the liver X receptor ␣dependent upregulation of ATP-binding cassette transporters, ABCA1 and ABCG1. 51
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Myocardial Adeno-Associated Virus Serotype 6 -␤ARKct Gene Therapy Improves Cardiac Function and Normalizes the Neurohormonal Axis in Chronic Heart Failure
Summary: A number of previous reports have suggested that cardiac G protein-coupled receptor kinase 2 inhibition, via the use of the peptide inhibitor ␤ARKct, could be a potential novel gene therapy for heart failure (HF). However, these studies tested the effects of ␤ARKct expression in transgenic mice or with short-term gene transfer experiments, and thus no clinically relevant conclusions about the long-term efficacy and adverse effects can be drawn. The present study investigated the long-term nature of ␤ARKct gene therapy in HF, providing proof of concept for its sustained therapeutic effects in the context of a relevant experimental model of HF.
Taking advantage of adeno-associated virus-mediated gene transfer, which enables efficient and sustained transgene expression, cardiac ␤ARKct gene delivery restored contractile dysfunction and reversed cardiac remodeling of chronically failing hearts. Mechanistically, this appears to be mediated by a normalization of cardiac ␤-adrenergic receptor signaling as well as lowering of gene expression associated with adverse left ventricular remodeling. Moreover, long-term myocardial ␤ARKct expression leads to neurohormonal feedback decreasing the hyperactivity of the sympathetic nervous system and renin-angiotensin-aldosterone axis in HF. Finally, ␤ARKct therapeutic properties are superior even to metoprolol, a clinically established HF therapy in humans, which is able only to prevent but not reverse (as the ␤ARKct did) progressive deterioration of contractile function. Therefore, this study shows that ␤ARKct gene therapy can be of long-term therapeutic value in HF, although testing of ␤ARKct gene therapy in large animals and in patients will ultimately define its place in the HF therapeutic armamentarium.
Conclusion: Long-term cardiac adeno-associated virus serotype 6-␤ARKct gene therapy in HF results in sustained improvement of global cardiac function and reversal of remodeling at least in part as a result of a normalization of the neurohormonal signaling axis. In addition, ␤ARKct alone improves outcomes more than a ␤-blocker alone, whereas both treatments are compatible. These findings show that ␤ARKct gene therapy can be of long-term therapeutic value in HF. 52
Inhibition of Prolyl Hydroxylase Domain Proteins Promotes Therapeutic Revascularization
Summary: Therapeutic neovascularization represents an alternative treatment modality for patients with advanced ischemic coronary or peripheral artery occlusive disease. Numerous animal studies have established that angiogenesis of ischemic tissue can be enhanced with exogenous growth factors or vascular progenitor cells, and clinical studies have been initiated. However, clinical trials to date are negative or give conflicting results. The hypoxia-inducible transcription factor (HIF) is a master regulator controlling genes involved in several processes that promote neovascularization, making modulation of HIF activity an attractive approach for the treatment of ischemic disease. In normoxia, HIF-␣ is hydroxylated by the prolyl hydroxylases domain proteins (PHDs), leading to ubiquitylation of HIF-1␣ and subsequently degradation by the proteasome. In contrast, under acute hypoxia, the PHD activity is compromised, allowing the stabilization and translocation of HIF-␣ in the nucleus and upregulation of wide repertoire of genes involved in vessel growth. In the present study, we used short hairpin RNAs to downregulate murine PHD1, PHD2, or PHD3 levels and analyzed their efficiency as a therapeutic strategy in a model of mice hindlimb ischemia. We demonstrated that a direct inhibition of PHDs, and more particularly PHD3, promoted therapeutic revascularization via specific activation of proangiogenic molecules, including vascular endothelial growth factor-A and endothelial nitric oxide synthase, and proarteriogenic proinflammatory pathways. Therefore, silencing of PHDs by the transient and local upregulation of endogenous HIF-1␣ improves vessel growth in ischemic tissue. This study also paves the way for future strategy based on administration of small interfering RNAs directed against PHD to promote therapeutic revascularization in ischemic disease.
Conclusion:
We demonstrated that a direct inhibition of PHDs, and more particularly PHD3, promoted therapeutic revascularization. Furthermore, we showed that activation of the HIF-1 signaling pathway is required to promote this revascularization. 53
Estrogen Receptor-␤ Activation Results in S-Nitrosylation of Proteins Involved in Cardioprotection
Summary: Premenopausal women have reduced cardiovascular disease, and this protection is lost as women enter menopause. A number of studies in animal models have shown that estrogen treatment is cardioprotective. In contrast, the Women's Health Initiative showed no protection with hormone replacement therapy, although some questions have been raised about the age of the women at treatment. This difference emphasizes the need for a better understanding of the mechanism by which estrogen protects in animal studies. This study shows that estrogen acts via the ␤-estrogen receptor in the heart to increase the S-nitrosylation of many proteins that have been shown to be cardioprotective. S-nitrosylation is a common posttranslational protein modification with covalent attachment of a nitric oxide moiety to protein sulfhydryl residues. S-nitrosylation not only leads to changes in the structure and function of target proteins but also prevents the modified cysteine residue(s) from further oxidative modification. These data might prompt future researchers to investigate whether age-related alterations in nitric oxide signaling contribute to the lack of protection by estrogen treatment in older women. It has been suggested that NO signaling might decrease with age because of a decrease in the levels of tetrahydrobiopterin or an increase in arginase activity. Additionally, the finding that a ␤ -estrogenspecific agonist is protective provides a potential novel treatment therapy that might promote the beneficial effects of estrogen without specific adverse effects on other tissues such as the uterus.
Conclusion:
The activation of estrogen receptor-␤ (ER-␤) by DPN treatment leads to increased protein SNO and cardioprotection against ischemia/reperfusion injury, suggesting that long-term estrogen exposure protects hearts largely via activation of ER-␤ and nitric oxide/SNO signaling. 54
Enhancement of Myocardial Regeneration Through Genetic Engineering of Cardiac Progenitor Cells Expressing Pim-1 Kinase
Summary: A revolution in the treatment of heart disease has begun, initiated by stem cell-mediated myocardial regeneration. Despite initial enthusiasm, multiple experimental and clinical studies indicate that present-day stem cell-based myogenesis and regeneration approaches fall short of the efficacy desired for reconstitution of myocardium after cardiomyopathic injury. Three significant problems to surmount are poor initial survival of the donated cell population, the number of cells required to mediate reparative processes, and limited engraftment and persistence over time. Therefore, engineering stem cells to enhance their regenerative capacity by increasing their survival, proliferation, and persistence could provide drastic improvements in both cardiac structure and function. Toward that goal, we compared cardiac progenitor cells engineered to overexpress Pim-1, a prosurvival and proproliferation kinase, with unmodified cardiac progenitor cells to assess potential long-term benefits in an experimental infarction model. Results showed that long-term structural and functional benefits were gained only through the use of cardiac progenitor cells expressing Pim-1. Increased de novo formation of both myocardium and vascular structures was observed with the Pim-1-engineered cells relative to e940 Circulation December 20/27, 2011 control cells. Furthermore, the Pim-1-engineered cells persisted for Ͼ8 months in the recipient heart. Thus, our data demonstrate that Pim-1-mediated cellular reprogramming demonstrably enhances myocardial repair and regeneration while using fewer cells than typically required for such interventions, offering a novel strategy for cellular cardiomyoplasty that is superior to current treatment modalities.
Conclusion: Myocardial repair is significantly enhanced by genetic engineering of cardiac progenitor cells with Pim-1 kinase. Ex vivo gene delivery to enhance cellular survival, proliferation, and regeneration may overcome current limitations of stem cell-based therapeutic approaches. 55
Silent Information Regulator 1 Protects the Heart From Ischemia/Reperfusion
Summary: Reperfusion injury is a significant health problem in Western countries, but there is no medical treatment to effectively reduce it. We have shown previously that silent information regulator 1 (Sirt1), a class III histone deacetylase and a member of the sirtuin family, inhibits cell death in cardiomyocytes in response to stress and retards aging in the heart. The sirtuin family proteins play an important role in mediating lifespan extension induced by caloric restriction in lower organisms, and stimulation of sirtuins appears to increase lifespan in vertebrates in certain conditions. Because many mechanisms inducing lifespan extension make organisms resistant to stress, we hypothesized that stimulation of sirtuin may also make the heart more resistant to ischemic injury. In this study, we investigated the role of Sirt1 in mediating cardioprotection in a mouse model of ischemia/reperfusion. Although downregulation of endogenous Sirt1 exacerbated myocardial injury, upregulation of Sirt1 attenuated it, in response to ischemia/reperfusion. Sirt1 enhanced nuclear accumulation of FoxO1, a transcription factor regulating antioxidants and cell death/survival mechanisms, which in turn attenuated oxidative stress in the heart. Our results suggest that enhancing the function of Sirt1 is a promising modality to reduce myocardial injury in patients with acute myocardial infarction.
Conclusion: These results suggest that Sirt1 protects the heart from ischemia/reperfusion injury through upregulation of antioxidants and downregulation of proapoptotic molecules through activation of FoxO and decreases in oxidative stress. 56
Smooth Muscle Cells Orchestrate the Endothelial Cell Response to Flow and Injury
Summary: Local delivery of antiproliferative drugs limits restenosis but may increase thrombosis even late after intervention. Device implantation and drug administration can synergistically induce endothelial dysfunction and delay recovery, impairing vasoreactivity, enhancing platelet aggregation, and elevating tissue factor expression. As stents are placed in increasingly complex geometries in the face of local and systemic disease, in the presence of clot and inflammation, a complex spectrum of issues must be considered that can no longer be intuited or dissected from in vivo experiments. We developed a model flow system examining signaling in vascular cells under controlled physiological flows. Our data demonstrate a profound difference in endothelial cell biology in the presence and absence of smooth muscle cells and suggest a far more sophisticated regulatory interaction between alterations in hemodynamics from above and vessel wall from below than classically appreciated. Similar to the triad that governs venous thrombosis, we now observe that signaling within vascular endothelial and smooth muscle cells is set by the biochemical milieu established by blood, local flow disruptions, and the state of the wall and its cells. The relative effects of the stent itself on the cells may explain the enhanced sensitivity of the endothelium after local delivery of agents that interfere with mammalian target of rapamycin signaling, placing vessels at risk of thrombosis even late after the initial treatment. Flow models with multiple cell systems bring us back to Virchow and forward into the era of complex vascular interventions and emerging concepts in vascular biology.
Conclusion: The mTOR pathway is activated in endothelial cells (ECs) in response to luminal flow. Smooth muscle cells (SMCs)
inhibit this flow-induced stimulation of endothelial mTOR pathway. Thus, we now define a novel external stimulus regulating phosphorylation of S6RP and another level of EC-SMC crosstalk. These interactions may explain the impact of local antiproliferative delivery that targets SMC proliferation and suggest that future stents integrate design influences on flow and drug effects on their molecular targets. 57
Microparticles From Ischemic Muscle Promotes Postnatal Vasculogenesis
Summary: Advances in the field of vascular biology have led to the identification of vascular progenitor cells from bone marrow and non-bone marrow origin and the development of cell-based therapy to induce neovessel formation in ischemic tissues. However, a critical point is the identification of cellular mechanisms governing the ability of progenitor cells to differentiate into endothelial cells. The present study depicts a new concept in the mechanisms of postnatal vasculogenesis, proposing that submicron microparticles generated locally after ischemia are endogenous triggers for bone marrow progenitor cell differentiation. Identification of the differentiation signals may participate in the development of strategies designed to improve the therapeutic potential of cell-based therapy.
In addition, given the important role of vascular progenitor cells for neovascularization of ischemic tissue, the decrease in the number and activity of microparticles may contribute to impaired vascularization in aged patients with cardiovascular risk factors. Finally, these findings possibly provide new options for risk assessment in this patient population.
Conclusion: Microparticles produced during tissue ischemia stimulate progenitor cell differentiation and subsequently promote postnatal neovascularization. 58
Activin A and Follistatin-Like 3 Determine the Susceptibility of Heart to Ischemic Injury
Summary: The injured heart secretes proteins that influence its function. In this study, we characterize 2 new members of the cardiac "secretome," activin A and follistatin-like 3 (Fstl3), using genetic gain-and loss-of-function manipulations in mouse models. Activin A and Fstl3 expression was increased in heart after various injuries and in cultured myocytes after hypoxia/reoxygenation. Activin A protected myocytes from cell death, and this protective activity was antagonized by Fstl3, which functions as an extracellular inhibitory protein for activin A. Myocardial ischemia/reperfusion injury was reduced in mice administered activin A. Genetic ablation of Fstl3 in cardiac myocytes also diminished injury in response to ischemia/ reperfusion. We speculate that activin A and Fstl3 serve as sensors of cardiac stress and that their relative levels of expression influence the adaptive response of the heart to injury.
Conclusion: Activin A and Fstl3 are induced in heart by myocardial stress. Activin A protects myocytes from death, and this activity is antagonized by Fstl3. Thus, the relative expression levels of these factors after injury is a determinant of cell survival in the heart. 59
Differentiation of Allogeneic Mesenchymal Stem Cells Induces Immunogenicity and Limits Their Long-Term Benefits for Myocardial Repair
Summary: Heart failure after a myocardial infarction remains a significant cause of mortality. Many have advocated stem cell therapy to prevent the progression of adverse events, but initial
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clinical trials did not reproduce the extensive benefits reported in preclinical animal trials. Compared with stem cells from young, healthy individuals, cells derived from elderly patients were found to have a limited ability to restore cardiac function in nonreactive animals. This diminished regenerative capacity of the older patients' stem cells might partially explain the limited benefits of stem cell therapy. Allogeneic mesenchymal stromal cells (MSCs) are an enriched population of cells with advanced therapeutic properties. Allogeneic MSCs offer a source of young, healthy, highly regenerative stem cells for implantation into the postinfarct myocardium. However, it is unclear whether these cells can avoid immune surveillance and engraft in the heart, in part because most preclinical assessments of allogeneic MSC therapy were restricted to the first 8 to 12 weeks after cell implantation. This study included a 6-monthlong evaluation of outcomes after allogeneic MSC therapy. We found that, although MSCs are immunoprivileged and can engraft in the heart and improve cardiac function early after implantation, they acquire an immunogenic phenotype and are immune rejected later, after they differentiate into specialized cells. Our findings provide an explanation for the diverse responses to allogeneic MSCs reported in previous studies and caution that these cells appear to have only short-term clinical benefits for the heart. Modifying the late immunogenic phenotype of MSCs may produce prolonged benefits after implantation.
Conclusion:
The long-term ability of allogeneic MSCs to preserve function in the infarcted heart is limited by a biphasic immune response whereby they transition from an immunoprivileged to an immunogenic state after differentiation, which is associated with an alteration in major histocompatibility complex-immune antigen profile. 60
Regulatory T Cells Modulate Postischemic Neovascularization
Summary: A specific component of the immune system known as the CD4ϩCD25ϩ regulatory T cell (Treg) repertoire is specialized for the suppression of both T helper 1 and T helper 2 pathogenic immune responses against self-antigens or foreign antigens and controls T-cell homeostasis. Interestingly, modulation of Treg cell levels controls the progression of inflammatory diseases. In this regard, the reduction of Treg cell number and function in both B7-1/2-and CD28-deficient diabetic mice exacerbates diabetes mellitus. In addition, it has been shown that modulation of the Treg cell response controls the development of atherosclerotic lesions. However, the role of Treg cells in the control of postischemic neovascularization remains unknown. In the present study, we report that Treg cells are a critical modulator of vessel growth. We observed that profound Treg cell reduction caused by B7/CD28 deficiency or anti-CD25 treatment increased postischemic revascularization, and we showed that exogenous administration of Treg cells reduced vessel growth in this setting. These results provide new insights into the immune regulation of vessel growth and may lead to new therapeutic approaches that involve immune modulation with Treg cells. In particular, our findings suggest that modulation of the regulatory arm of the immune response could provide novel strategies for the treatment of ischemic diseases that target angiogenesis.
Conclusion: Treg cell response modulates postischemic neovascularization. 61
Rescue of Cardiomyopathy in Peroxisome Proliferator-Activated Receptor-␣ Transgenic Mice by Deletion of Lipoprotein Lipase Identifies Sources of Cardiac Lipids and Peroxisome Proliferator-Activated Receptor-␣ Activators
Summary: Metabolic syndrome and type 2 diabetes mellitus are dramatically increasing in prevalence worldwide. Cardiovascular disease is the leading cause of death among patients with diabetes mellitus, including a unique form of heart failure that is independent of coronary risk factors. Accumulation of myocardial lipid and alterations in cardiac fuel metabolism likely play an important role in cardiomyopathy in diabetic patients, a problem referred to as lipotoxic cardiomyopathy. This article explores several key questions related to the cause of diabetic heart disease such as, What is the contribution of excess fatty acid burning to contractile dysfunction? What is the source of excess fat, and does it activate peroxisome proliferator-activated receptor-␣ (PPAR-␣), an important transcriptional mediator of increased fatty acid uptake and use in the diabetic heart? We demonstrate in an animal model of lipotoxic cardiomyopathy that lipoprotein-triglycerides rather than free fatty acid are the primary contributor to cardiomyopathy. Furthermore, we link lipoprotein lipase hydrolysis of very-low-density lipoproteins to activation of PPAR␣, suggesting that lipoprotein lipase plays a critical role in both driving lipid excess and generating ligand for activation of PPAR␣, thus promoting excess FA utilization pathways. Finally, our data suggest that lipid excess is associated with mitochondrial dysfunction, a likely mechanism for cardiac failure in patients with lipotoxic cardiomyopathy. Future studies to identify the specific PPAR␣ ligand generated by lipoprotein lipase may help guide therapeutic strategies for diabetic heart failure.
Conclusion: Myosin heavy chaina (MHC)-PPAR␣ mouse hearts acquire excess lipoprotein-derived lipids. LpL deficiency rescues myocyte triglyceride accumulation, mitochondrial gene regulatory derangements, and contractile function in MHC-PPAR␣ mice. Finally, LpL serves as a source of activating ligand for PPAR␣ in the cardiomyocyte. 62
Podoplanin-Expressing Cells Derived From Bone Marrow Play a Crucial Role in Postnatal Lymphatic Neovascularization
Summary: In this study, we identified podoplanin-expressing lymphatic endothelial progenitor cells derived from bone marrow. Injection of these podoplanin-expressing lymphatic endothelial progenitor cells into various animal models showed the contribution of these cells to the formation of new lymphatic vessels through direct transdifferentiation and paracrine effects. This lymphatic vesselforming capability can be used for the treatment of lymphedema or chronic unhealed wounds, which are characterized by lymphatic vascular insufficiency. Moreover, this study demonstrated an increase in the number of circulating lymphatic endothelial progenitor cells in tumor-bearing mice, suggesting that lymphatic endothelial progenitor cells are correlated with tumor-associated lymphatic vascular growth. This property can be harnessed for the development of a biomarker for monitoring tumor burden, tumor growth, and/or metastasis.
Conclusion:
Our results provide compelling evidence that BMderived podoplanin ϩ cells, a previously unrecognized cell type, function as lymphatic endothelial progenitor cells and participate in postnatal lymphatic neovascularization through both lymphvasculogenesis and lymphangiogenesis. 63
Protein Tyrosine Phosphatase 1B, a Major Regulator of Leptin-Mediated Control of Cardiovascular Function
Summary: Protein tyrosine phosphatase 1B (PTP1B) controls insulin and leptin sensitivity through its ability to directly inactivate catalytically phosphorylated tyrosines. Because deletion of PTP1B has been reported to improve insulin and leptin sensitivity and to protect rodents against the development of obesity and type II diabetes mellitus, PTP1B inhibitors are under development to treat metabolic disorders. The present study analyzed the cardiovascular function of PTP1B knockout mice and reports that PTP1B deletion increased sympathetic tone and enhanced mean arterial pressure, which high-e942 Circulation December 20/27, 2011 lights the possible deleterious consequences of global PTP1B inhibitors in obese patients with type II diabetes mellitus, who are already prone to the development of hypertension. This study further reports that the control mice (Balb/c mice) did not develop an increase in blood pressure in response to leptin infusion despite an increased sympathetic tone. The significant decreased vascular adrenergic reactivity reported both in vivo and ex vivo (isolated artery) and supported by the reduction in vascular ␣1-adrenergic receptor expression suggests that adrenergic desensitization, in response to sympathetic overdrive, may be a protective mechanism against the development of hypertension. Taken together, these data suggest that caution is warranted in the consideration of PTP1B inhibitors as antidiabetic drugs and further suggest that mechanisms that interfere with adrenergic desensitization may contribute to the hypertension observed in obese individuals with high levels of leptin.
Conclusion: These data indicate that PTP1B is a key regulator of the cardiovascular effects of leptin and that reduced vascular adrenergic reactivity provides a compensatory limit to the effects of leptin on mean arterial pressure. 64
Mineralocorticoid Modulation of Cardiac Ryanodine Receptor Activity Is Associated With Downregulation of FK506-Binding Proteins
Summary: Defective calcium handling is a key contributor to the pathophysiology of heart failure, not only in the weakening of the heart's ability to pump blood but also in the erratic heart beats that cause sudden death. Research conducted to understand the molecular mechanisms underlying those fatal arrhythmias has focused mainly on downstream mechanisms (the defective calcium-handling processes) rather than the causes. The present study highlights the role of the cardiac aldosterone pathway as an upstream primary molecular event that leads to defective calcium handling. Combining ex vivo and in vivo (transgenic mice) approaches and using state-of-the-art Ca2ϩ imaging, electrophysiology, and biochemistry methods, we provide the first evidence that downregulation of FK506 binding proteins (also known as calstabins) through the aldosterone pathway causes defectiveness of ryanodine receptor activity, which has been associated with the common pathogenic mechanism of sudden cardiac death and heart failure. In addition, these findings underline the potential of mineralocorticoid receptor antagonists as antiarrhythmic therapy.
Conclusion:
We suggest that in addition to modulation of Ca2ϩ influx, overstimulation of the cardiac mineralocorticoid pathway in the heart might be a major upstream factor for aberrant Ca2ϩ release during diastole, which contributes to cardiac arrhythmia in heart failure. 65
Priming With Angiopoietin-1 Augments the Vasculogenic Potential of the Peripheral Blood Stem Cells Mobilized With Granulocyte Colony-Stimulating Factor Through a Novel Tie2/Ets-1 Pathway
Summary: Although intracoronary cell infusion is the most popular method of cell delivery for cardiovascular disease because of its convenience, its efficacy is limited by the poor engraftment rate to ischemic myocardium after intracoronary delivery. We found that peripheral blood stem cells mobilized with granulocyte colonystimulating factor (mobPBSCs) expressed high levels of the Tie2 receptor compared with naïve peripheral blood mononuclear cells, suggesting that angiopoietin-1 could be a very specific priming agent for mobPBSCs. Primed cells with angiopoietin-1 increased the expression of adhesion molecules and commitment to endothelial lineage, leading to improved engraftment and vasculogenesis. These results imply that priming with angiopoietin-1 can significantly improve the therapeutic efficacy of stem cells. The approach outlined here in which angiopoietin-1 is used for priming cells ex vivo before infusion requires further clinical studies to demonstrate efficacy.
Conclusion:
The short-term priming with cartilage oligomeric matrix protein (COMP)-Ang1 may be a feasible and promising option to activate mobPBSCs by enhancing differentiation and adhesiveness and to improve the efficacy of cell therapy for ischemic diseases. 66
Hyperhomocysteinemia Promotes Inflammatory Monocyte Generation and Accelerates Atherosclerosis in Transgenic Cystathionine ␤-Synthase-Deficient Mice
Summary: Hyperhomocysteinemia (HHcy) is an independent risk factor for cardiovascular diseases. In this study, we established novel disease models with severe HHcy and hypercholesterolemia in which the mouse cystathionine ␤-synthase (CBS) and apolipoprotein E (apoE) genes are deficient and an inducible human CBS or diseaserelevant mutant CBS (S466L) transgene is introduced to circumvent the neonatal lethality of CBS deficiency (Tg-hCBS apoEϪ/Ϫ CbsϪ/Ϫ or Tg-S466L CbsϪ/Ϫ mice). First, we demonstrated that severe HHcy accelerated atherosclerosis and inflammatory monocyte/macrophage accumulation in the lesion and increased plasma tumor necrosis factor-a and monocyte chemoattractant protein-1 levels in Tg-hCBS apoEϪ/Ϫ CbsϪ/Ϫ mice fed a high-fat diet. Thus, systemic inflammation possibly mediated the enhanced Ly-6C monocyte/macrophage accumulation in the lesion. We also found that severe HHcy induced Ly-6Chi and Ly-6Cmid inflammatory monocyte subset expansion in the peripheral blood, spleen, and bone marrow in Tg-hCBS apoEϪ/Ϫ CbsϪ/Ϫ and Tg-S466L Cbs mice independently of hyperlipidemia. Furthermore, we discovered that L-homocysteine, but not L-cysteine, promoted Ly-6Chi monocyte subset survival and Ly-6Cmid subset differentiation in cultured primary mouse splenocytes. Finally, we reported that Hcy-induced Ly-6Cmid subset differentiation was abolished by superoxide dismutase/catalase or the NAD(P)H oxidase inhibitor apocynin. Taken together, these results show that HHcy selectively promoted Ly-6C monocyte subset differentiation and enhanced their accumulations in the lesion, contributing to accelerated atherosclerosis in HHcy. Thus, the present study provides important insights into HHcy-related cardiovascular disease.
Conclusion: HHcy promotes differentiation of inflammatory monocyte subsets and their accumulation in atherosclerotic lesions via NAD(P)H oxidase-mediated oxidant stress. 67
Genetic Deficiency of Plasminogen Activator Inhibitor-1 Promotes Cardiac Fibrosis in Aged Mice: Involvement of Constitutive Transforming Growth Factor-␤ Signaling and Endothelial-to-Mesenchymal Transition
Summary: Cardiac fibrosis, defined as the proliferation of interstitial fibroblasts and accumulation of extracellular matrix components in the heart, is a common consequence of cardiovascular disease, including acute myocardial infarction and hypertension. Cardiac fibrosis contributes to the development of ventricular dysfunction (systolic and diastolic), heart failure, and arrhythmias. Although fibrosis is predictably identified in end-stage heart disease, the origin of fibroblasts contributing to the excessive synthesis of collagen in the fibrotic heart is controversial. At present, there is no effective treatment to prevent or to reverse cardiac fibrosis. The present study elucidates the molecular basis of cardiac fibrosis using a murine model of age-dependent spontaneous cardiac fibrosis that develops in the absence of the plasminogen activator inhibitor-1 gene. The present study suggests that the cardiac fibrosis in plasminogen activator inhibitor-1-deficient mice is due to increased inflammation, elevated levels of transforming growth factor-␤, and induction
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of transforming growth factor-␤-induced profibrotic responses. Plasminogen activator inhibitor-1-deficient endothelial cells appear to be more susceptible to the phenomenon called endothelialmesenchymal transition in response to transforming growth factor-␤ via induction of both Smad and ERK1/2 MAPK pathways. These findings provide new insights into molecular mechanisms of cardiac fibrosis and suggest that physiological plasminogen activator inhibitor-1 levels help to protect the heart from age-dependent fibrogenesis. Thus, specific disruption of activated Smad and ERK1/2 MAPK signaling pathways with small-molecule inhibitor(s) may be useful in limiting endothelial-mesenchymal transition and may inform a novel therapeutic approach to prevent and treat cardiac fibrosis in humans.
Conclusion:
These results indicate that spontaneous activation of both Smad and non-Smad transforming growth factor-␤ signaling may contribute to profibrotic responses in aged P-1-deficient mice hearts and establish a possible link between endothelial-tomesenchymal transition and cardiac fibrosis in PAI-1-deficient mice. 68
High-Density Lipoprotein Suppresses the Type I Interferon Response, a Family of Potent Antiviral Immunoregulators, in Macrophages Challenged With Lipopolysaccharide
Summary: The cardioprotective effect of high density lipoprotein (HDL) is thought to involve the clearance of cholesterol from lipid-laden macrophages in the artery wall. However, recent evidence suggests that HDL might also inhibit atherogenesis by combating inflammation. To identify potential anti-inflammatory mechanisms, we challenged macrophages with lipopolysaccharide, an inflammatory microbial ligand for Toll-like receptor 4. We found that HDL inhibited the expression of many genes normally induced by lipopolysaccharide. Unexpectedly, expression of inflammatory cytokines like tumor necrosis factor-a and interleukin-6 was not inhibited by HDL. Instead, the major target was the type I interferon response pathway, a family of potent viral immunoregulators controlled by Toll-like receptor 4 and the TRAM/TRIF signaling pathway. Moreover, the ability of HDL to inhibit gene expression was independent of cellular cholesterol stores. Our observations suggest that TRAM translocates to intracellular compartments when macrophages are exposed to HDL. This in turn impairs subsequent signaling by Toll-like receptor 4 and TRIF, which plays a key role in triggering the type I interferon response. Our results may be physiologically relevant because mice deficient in the major protein of HDL exhibited 6-fold higher levels of interferon-␤, a key regulator of the type I interferon response, than did wild-type mice when the animals were infected with a Gram-negative bacterium. We conclude that HDL inhibits a subset of lipopolysaccharidestimulated macrophage genes that regulate the type I interferon response and that its action is independent of sterol metabolism. These findings raise the possibility that regulation of macrophage genes by HDL might link innate immunity and cardioprotection.
Conclusion: HDL inhibits a subset of lipopolysaccharide-stimulated macrophage genes that regulate the type I interferon response, and its action is independent of sterol metabolism. These findings raise the possibility that regulation of macrophage genes by HDL might link innate immunity and cardioprotection. 69
Alterations of Phospholamban Function Can Exhibit Cardiotoxic Effects Independent of Excessive Sarcoplasmic Reticulum Ca2؉-ATPase Inhibition
Summary: This study shows that correcting abnormal myocyte Ca2ϩ flow can serve as a powerful tool against heart failure. Intracellular Ca2ϩ cycling, which enables the heart muscle to contract and relax, has been known for many years to be disrupted in heart failure. Although it has been unclear whether the disturbance is contributing to cardiac dysfunction or a secondary consequence, the identification of a rare phospholamban mutation (PLNR9C) provided the first evidence that altered Ca2ϩ flow alone is sufficient to incite cardiac remodeling processes that lead to dilated cardiomyopathy and terminal heart failure in humans. Transgenic mice with cardiac expression of PLNR9C also develop dilated cardiomyopathy and die prematurely; counteracting the slowing of sarcoplasmic reticulum Ca2ϩ uptake in such mice by releasing sarco(endo)plasmic reticulum Ca2ϩ-ATPase (SERCA2a) via ablation of endogenous PLN (while maintaining PLNR9C expression) dose dependently delays the onset of heart failure and prolongs survival up to 3-fold. However, even sarcoplasmic reticulum Ca2ϩ uptake rates that are faster than normal are not sufficient to prevent the development of late-onset heart failure in these mice. Thus, 2 independent principles of PLN dysfunction can trigger the development of heart failure. One is excessive SERCA2a inhibition. Because PLNR9C is phosphorylation deficient, the second may be the inability to turn SERCA2a activity up and down by phosphorylation and dephosphorylation of PLN. Apparently, increasing the ratio of SERCA2a to PLN is a potent target for the treatment of heart failure that is caused by Ca2ϩ defects, but such strategies may be most successful if they allow efficient regulation of PLN activity.
Conlusion:
The data demonstrate an association between the dosedependent inhibition of SERCA2a activity by PLNwt and the time of onset of heart failure and show that a weak inhibitor of SERCA2a, PLNR9C, which is diminished in its ability to modify the level of SERCA2a activity, leads to heart failure despite fast sarcoplasmic reticulum Ca2ϩ reuptake. 70
Lecithin: Cholesterol Acyltransferase Expression Has Minimal Effects on Macrophage Reverse Cholesterol Transport In Vivo
Summary: Lecithin:cholesterol acyltransferase (LCAT) is a key enzyme in the metabolism of high-density lipoprotein (HDL). It converts "free" cholesterol (form effluxed from macrophages) to cholesteryl ester, permitting the formation and progressive enlargement of mature HDL particles. It has long been believed that LCAT is critical in facilitating the process of reverse cholesterol transport, leading to the concept that upregulation of LCAT activity is a therapeutic target for atherosclerosis, but this has never been experimentally proven. Using a validated assay of macrophage-specific reverse cholesterol transport in mice, we explored the effects of both LCAT overexpression (which raises HDL cholesterol [HDL-C] levels) and LCAT deficiency (which reduces HDL-C levels). Surprisingly, LCAT overexpression, despite markedly raising HDL-C, did not promote macrophage reverse cholesterol transport. Even coexpression of scavenger receptor BI or cholesteryl ester transfer protein, both of which transfer cholesterol ester out of HDL and facilitate its return to the liver, failed to convert LCAT overexpression into an intervention that promotes reverse cholesterol transport. Furthermore, complete LCAT deficiency, despite reducing HDL-C to Ͻ5% of normal levels, reduced reverse cholesterol transport by only Ϸ50%, and moderate LCAT deficiency, despite moderately reducing HDL-C levels, had no effect on reverse cholesterol transport. These studies challenge the long-held belief that LCAT is critical for macrophage reverse cholesterol transport and bring into question whether LCAT activation would necessarily be an atheroprotective intervention even though it raises HDL-C levels. The results are consistent with a growing trend focused on HDL quality and function rather than simply plasma HDL-C levels as a target for the development of new therapies.
Conclusion: These results demonstrate that LCAT overexpression does not promote an increased rate of macrophage reverse cholesterol transport (RCT). Although LCAT activity does become rate limiting in the context of complete LCAT deficiency, RCT is reduced by only 50% even in the absence of LCAT. These data suggest that macrophage RCT may not be as dependent on LCAT activity as has previously been believed. 71
Failure of Postnatal Ductus Arteriosus Closure in Prostaglandin Transporter-Deficient Mice
Summary: Prostaglandins are small signaling molecules that control multiple bodily functions. Many people manipulate their prostaglandin levels without knowing it because nonsteroidal antiinflammatory drugs such as aspirin act by blocking prostaglandin synthesis. Among their actions, prostaglandins help to keep open a blood vessel in the fetus called the ductus arteriosus and to close the ductus appropriately after birth. The present study focuses on the mechanism by which prostaglandin signaling is shut off. Previous experiments using cells grown in glass dishes have demonstrated that a carrier protein called PGT transports prostaglandins from the blood into the cell interior, where an enzyme inactivates them. The prediction from these studies would be that inactivating or blocking PGT in an experimental animal or human being would cause prostaglandin levels to rise, resulting in abnormal prostaglandin signaling from 1 cell to another. This study used genetic engineering methods to inactivate all PGT carriers in mice. Mice lacking PGT from conception failed to close their ductus arteriosus normally at birth, resulting in their death on or about the first day of life. The results have implications for humans because failure to close the ductus arteriosus after birth is a common congenital disorder.
Conclusion: PGT plays a critical role in closure of the ductus arteriosus after birth by ensuring a reduction in local and/or circulating prostaglandin E 2 concentrations. 72
Thioredoxin-1 Gene Therapy Enhances Angiogenic Signaling and Reduces Ventricular Remodeling in Infarcted Myocardium of Diabetic Rats
Summary: The higher incidence of post-myocardial infarction angina, larger infarcts, severity of myocardial functional disorder, and unfavorable prognosis among diabetic individuals who develop such complications has been correlated with oxidative stress-mediated impairment of angiogenesis. Moreover, diabetes reflects a challenging condition in which the usual revascularization techniques such as coronary artery bypass surgery and percutaneous transluminal coronary angioplasty tend to fail, thereby leaving many diabetic patients with ischemic heart disease with no options for treatment. Maintenance of a balanced redox status in the microenvironment might aid in alleviating many diabetes-mediated complications, particularly those related to impaired angiogenesis. Our preclinical findings are supportive of the concept that in a diabetic milieu, impaired angiogenesis is not only caused by the downregulation of angiogenic growth factors but is also dependent on excessive oxidative stress and the lack of responsive antioxidant systems. For the first time, our unique results have identified the in vivo angiogenic potential of thioredoxin-1 and substantiated its antioxidative and antiapoptotic properties in the setting of myocardial infarction in a diabetic milieu. We therefore propose to treat diabetes-mediated impairment of angiogenesis by normalizing and stabilizing the redox microenvironment in the myocardium by means of thioredoxin-1 gene therapy, thereby reducing oxidative stress and cell death and inducing neovessel formation and maturation, subsequently reducing ventricular remodeling after a myocardial infarction. Our novel approach of Trx1 gene delivery may prove to be a strategic therapeutic modality in the treatment of diabetes-related cardiac failure and may ultimately improve quality of life and mitigate disease progression in affected individuals.
Conclusion: This study demonstrates for the first time that impairment of angiogenesis and myocardial dysfunction can be regulated by Ad.Trx1 gene therapy in streptozotocin-induced diabetic rats subjected to infarction. 73
Impaired Macrophage Migration Inhibitory Factor-AMP-Activated Protein Kinase Activation and Ischemic Recovery in the Senescent Heart
Summary: Cardiovascular disease remains the most frequent single cause of death among persons Ͼ70 years of age. The aged heart is inherently more susceptible to injury during myocardial ischemia. However, the cause(s) of this increased susceptibility remain poorly understood. On the basis of both in vitro and in vivo observations, AMP-activated protein kinase (AMPK) has emerged as an important component of the cardioprotective response against ischemic injury. The present study provides the first evidence that the senescent heart manifests an impaired AMPK activation in response to ischemic stress, which is associated with more severe myocardial damage during ischemia and reperfusion. This study also showed that cardiomyocyte production of an upstream activator of AMPK, macrophage migration inhibitory factor, is impaired in the aged heart. Importantly, supplementary administration of macrophage migration inhibitory factor by pharmacological or genetic approaches restored AMPK function in the aged heart, limited ischemic damage, and improved cardiac function after ischemia and reperfusion. Evidence is also provided that defective hypoxia-inducible factor-1, ␣ subunit (HIF-1␣) in the senescent heart may account for the impairment in macrophage migration inhibitory factor expression. An aging-associated decrease in the function of the HIF-1␣macrophage migration inhibitory factor axis may play a causative role in the intolerance of the senescent heart to ischemic injury. Pharmacological interventions that restore migration inhibitory factor signaling and AMPK activity in the senescent heart may be a useful means to reduce cardiac damage caused by ischemic injury in older individuals.
Conclusion: An impaired migration inhibitory factor (MIF)-AMPK activation response in senescence thus may be attributed to an aging-associated defect in hypoxia-inducible factor 1␣, the transcription factor for MIF. In the clinical setting, impaired cardiac hypoxiainducible factor 1␣ activation and consequent reduced MIF expression may play an important role in the increased susceptibility to myocardial ischemia observed in older cardiac patients. 74
Conditional Overexpression of Neuronal Nitric Oxide Synthase Is Cardioprotective in Ischemia/Reperfusion
Summary: Myocardial ischemia is the major threat to cardiac myocytes in acute myocardial infarction. Yet, despite infarct-sparing interventions like early reperfusion therapy by percutaneous coronary intervention, myocardial scars develop, even if call-to-balloon time is Ͻ90 minutes. Therefore, there is a medical need for additional options to enhance myocardial resistance to ischemia. Ischemic preconditioning or drugs that stimulate cardioprotective signaling (pharmacological preconditioning) might prove to be beneficial in this setting. Endothelial nitric oxide synthase (NOS) and inducible NOS have already been proven to be cardioprotective in ischemia/reperfusion experiments. We now add data on the remaining NOS isoform, neuronal NOS (or NOS1). Neuronal NOS overexpression in an animal model restored myocardial function compared with wild-type mice after reperfusion caused by inhibition of xanthine oxidoreductase (which decreased reactive oxygen series formation) and by inhibition of cytochrome c oxidase (which decreased myocardial oxygen consumption). It appears that transgenic overexpression in the myocardium of each of the 3 NOS isoforms acts as a net and prevents reperfusion damage, at least in part. However, the precise molecular mechanism behind each isoform is probably different, depending on the subcellular localization of each isoform. It has also been demonstrated that neuronal NOS may inhibit arrhythmogenesis by maintaining intracellular Ca2ϩ homeostasis in cardiomyocytes via S-nitrosylation of Ca2ϩhandling proteins, leading to reductions in ventricular arrhythmias
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and death after myocardial infarction. Hence, adding NO as a drug to the therapeutic regimen in acute myocardial infarction is likely to be less successful than increasing neuronal NOS expression in the myocardium.
Conclusion:
We demonstrated that conditional transgenic overexpression of nNOS resulted in myocardial protection after ischemia/ reperfusion injury. Besides a reduction in reactive oxygen species generation, this might be caused by nitrite-mediated inhibition of mitochondrial function, which reduced myocardial oxygen consumption already under baseline conditions. 75 Conclusion: These results are the first to show that MBL is abundantly present and locally produced during early atherogenesis. Local MBL expression, by myeloid cells, is shown to critically control development of atherosclerotic lesions. 76
Macrophage-Specific Expression of Mannose-Binding Lectin Controls Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice
Continuous Glycoprotein-130 -Mediated Signal Transducer and Activator of Transcription-3 Activation Promotes Inflammation, Left Ventricular Rupture, and Adverse Outcome in Subacute Myocardial Infarction
Summary: High serum interleukin-6 (IL-6) levels in patients with myocardial infarction or heart failure are consistently associated with reduced cardiac function and a poor outcome (ie, increased morbidity and mortality). This observation contrasts with experimental data that suggest cardioprotective effects mediated by the common receptor subunit glycoprotein-130 (gp130), of IL-6 cytokines. IL-6 cytokine-mediated gp130 signaling involves a complex network of activating and terminating mechanisms controlling 3 major downstream signaling pathways: janus kinase/signal transducer and activator of transcription (STAT), cytoplasmic protein tyrosine phosphatase/extracellular signal-regulated kinase, and phosphoinositide-3-kinase/Akt. The degree and duration of downstream signaling activation depend at least in part on a single tyrosine residue, Y-757, at the gp130 receptor. In cardiomyocyte-specific gp130Y757F mu-tant mice (Y757F), the Y-757-dependent control is ablated by a point mutation leading to prolonged and enhanced JAK/STAT activation, whereas ERK and Akt signaling is absent. In response to myocardial infarction, Y757F mice displayed higher mortality associated with an increased left ventricular rupture rate, sustained cardiac inflammation, and heart failure. These adverse effects result from prolonged and enhanced STAT3 activation, increased expression of IL-6, and upregulated mannose-binding-lectin-C-mediated complement activation. Pharmacological inhibition of the complement system by cobra venom factor or genetic reduction of STAT3 prevented sustained inflammation and lowered left ventricular rupture rate, heart failure, and mortality in subacute myocardial infarction. This study unravels the potential adverse effects of high IL-6 cytokine levels after myocardial infarction in settings with impaired gp130 downstream signaling. In this regard, sustained IL-6 -dependent and gp130-mediated STAT3 activation in subacute infarction promotes cardiac inflammation, adverse remodeling, and heart failure.
Conclusion: Impaired downregulation of gp130-mediated STAT3 activation in subacute infarction promotes cardiac inflammation, adverse remodeling, and heart failure, suggesting a potential causative role of high interleukin-6 serum levels after myocardial infarction. 77
Tumor Suppressor Ras-Association Domain Family 1 Isoform A Is a Novel Regulator of Cardiac Hypertrophy
Summary: Understanding the molecular mechanisms of hypertrophy is key in elucidating the pathogenesis of heart failure. Our study is based on 2 premises: first, many factors that positively mediate hypertrophy have been identified in recent years, but little is known about molecules that counteract and therefore limit cardiac growth. Second, a series of mutations in genes of the Ras-signaling pathway have recently been identified, which associate certain cancers with hypertrophic cardiomyopathy (eg, in Noonan and Costello syndromes). This led us to hypothesize that negative regulators of the Ras pathway may also limit cardiac growth in common conditions such as pressure overload. One such negative regulator in cancer is the recently described tumor suppressor protein Ras-association domain family 1 isoform A (RASSF1A). We therefore investigated the role of this molecule in negatively regulating myocardial hypertrophy. We subjected mice with genetic ablation of Rassf1a gene to transverse aortic constriction. A massive increase in the hypertrophic response, fibrosis, and left ventricular dilatation were observed in these animals. We further showed that RASSF1A acts through the inhibition of Ras at the level of Ras/Raf1 interaction, thus blocking the downstream extracellular regulated kinase 1/2 signaling pathway. Furthermore, a significant downregulation of RASSF1A expression by Ϸ50% was observed in failing human hearts, indicating its involvement in the development of heart failure. Our findings establish RASSF1A as a novel inhibitor of cardiac hypertrophy both in mouse and human and may provide opportunities for the development of novel therapeutic strategies for heart failure by targeting this molecule.
Conclusion: Our data establish RASSF1A as a novel inhibitor of cardiac hypertrophy by modulating the extracellular regulated kinase 1/2 pathway. 78
Cardiac Myosin Binding Protein-C Phosphorylation in a ␤-Myosin Heavy Chain Background
Summary: Discovering the function of cardiac myosin binding protein-C (cMyBP-C) is important clinically because mutations in the protein can cause familial hypertrophic cardiomyopathy. cMyBP-C modulates myosin assembly and helps to control cardiac contractility. Decreased cMyBP-C phosphorylation is associated with the development of heart failure or pathological hypertrophy in mice and humans. One of the major questions with respect to the many mouse models used to understand human disease is their relevance. This is of particular concern when dealing with the contractile apparatus of the heart because the major motor protein in the mouse heart, a -myosin heavy chain (MyHC), differs from the human heart, which contains the slower ␤ -MyHC. In this study, we defined the impact(s) of cMyBP-C phosphorylation in a ␤ -MyHC background to understand whether cMyBP-C-mediated cardioprotection in the face of ischemic injury could work in a myosin background that is more like the human's. Our data confirm that cMyBP-C phosphorylation is essential in a ␤ -MyHC background, and, in contrast to the a -MyHC background, a phosphomimetic cMyBP-C improves the rates of contraction and relaxation while also remaining cardioprotective. These results suggest that cMyBP-C phosphorylation can have direct effects on the contractile properties and sarcomere organization of the human heart and that it can also protect the heart from ischemic injury. Selective cMyBP-C phosphorylation may provide a novel therapeutic strategy to improve muscle function in patients in the early or even late stages of heart failure.
Conclusion: cMyBP-C phosphorylation is necessary for basal myocardial function in the ␤ -MyHC background and can preserve function after ischemia/reperfusion injury. Our studies justify exploration of cMyBP-C phosphorylation as a therapeutic target in the human heart. 79
Gene Transfer of Inducible Nitric Oxide Synthase Affords Cardioprotection by Upregulating Heme Oxygenase-1 via a Nuclear Factor-B-Dependent Pathway
Summary: Although nitric oxide donors such as nitroglycerin have been used as antianginal and preload-reducing agents for more than a century, their cardiovascular effects are still not entirely understood. In 1997, we proposed the nitric oxide hypothesis of ischemic preconditioning, which postulates that the cardioprotection afforded by the late phase of preconditioning is underlain by the upregulation of the inducible isoform of nitric oxide synthase (iNOS) and the attendant increase in the production of nitric oxide. This hypothesis subsequently has been validated and extended to other organs, including kidney and intestine, which implies that upregulation of iNOS is a central axis whereby tissues protect themselves from ischemia. However, the molecular basis responsible for the protective effects of iNOS in the heart remains largely unknown. In the present investigation, we have discovered the existence of a close functional coupling between cardiac iNOS and cardiac heme oxygenase-1 (HO-1), another major cytoprotective protein. We found that upregulation of cardiac iNOS via gene transfer leads to increased expression of HO-1 and that this occurs via nuclear translocation of the transcription factor nuclear factor-kB and its binding to the promoter of the HO-1 gene. The identification of a coupling between iNOS and HO-1 has significant implications for the fields of gene therapy and ischemia/reperfusion injury, both from a conceptual and a therapeutic standpoint. For example, activation of the iNOS-HO-1 module via pharmacological means or gene therapy may prove beneficial in patients with ischemic heart disease.
Conclusion: This study demonstrates for the first time the existence of a close functional coupling between cardiac iNOS and cardiac HO-1: iNOS upregulates HO-1 by augmenting nuclear factor-kB binding to the region of the HO-1 gene promoter from -468 to -459 bp, and HO-1 then mediates the cardioprotective effects of iNOS. These results also reveal an important role of nuclear factor-kB in both basal and iNOS-induced expression of cardiac HO-1. Collectively, the present findings significantly expand our understanding of the regulation of cardiac HO-1 and of the mechanism whereby iNOS exerts its cardioprotective actions. 80
Titin is a Target of Matrix Metalloproteinase-2: Implications in Myocardial Ischemia/Reperfusion Injury
Summary: In addition to the well-known extracellular effects of matrix metalloproteinases (MMPs), we provide evidence that MMP-2 is localized inside the cardiac myocyte, near the Z-disk region of the sarcomere. We also show that on acute ischemia/ reperfusion injury, MMP-2 is activated and proteolyses titin, the largest known protein that plays a crucial role in both the diastolic and systolic function of the heart. Titin contains several cleavage motifs for MMP-2, and its proteolysis is reduced in hearts protected by pharmacological inhibition of MMP activity and in MMP-2deficient hearts. This study provides new insights into the pathophysiological mechanism of ischemia/reperfusion injury and suggests that MMP inhibitors might be a useful strategy for reducing reperfusion injury.
Conclusion: MMP-2 localizes to titin at the Z-disk region of the cardiac sarcomere and contributes to titin degradation in myocardial ischemia/reperfusion injury. 81
Targeting Lymphatic Vessel Activation and CCL21 Production by Vascular Endothelial Growth Factor Receptor-3 Inhibition Has Novel Immunomodulatory and Antiarteriosclerotic Effects in Cardiac Allografts
Summary: Despite very good short-term results, the long-term survival of cardiac allograft recipients has not improved. Although the currently used immunosuppressive drugs efficiently inhibit the proliferation of alloreactive T cells, they have severe side effects such as infections, malignancies, and metabolic problems and do not prevent the development of cardiac allograft arteriosclerosis, a manifestation of chronic rejection. Here, we used rat and mouse heart transplantation models to investigate whether lymphatic vesseltargeted therapies modulate the exit of antigen-presenting cells from the allograft to secondary lymphoid organs and the development of acute and chronic rejection. Chronic inflammation increased the expression of allograft lymphatic vessel growth factor (VEGF-C) and induced lymphangiogenesis in rat cardiac allografts. Lymphatic vessels were active and functional in that they contained antigenpresenting cells and expressed dendritic cell chemokine CCL21 and VEGF-C receptor VEGFR-3. Inhibition of VEGFR-3 with gene therapy or monoclonal antibodies decreased allograft CCL21 production, dendritic cell traffic to the secondary lymphoid organs, and the development of acute and chronic cardiac allograft rejection. These results suggest VEGFR-3 inhibition as a novel lymphatic vessel-targeted immunomodulatory therapy for cardiac allograft rejection and indicate an active role for lymphatic vessels in inflammation-driven arteriosclerosis.
Conclusions:
These results show that VEGFR-3 participates in immune cell traffic from peripheral tissues to secondary lymphoid organs by regulating allograft lymphatic vessel CCL21 production and suggest VEGFR-3 inhibition as a novel lymphatic vesseltargeted immunomodulatory therapy for cardiac allograft rejection and arteriosclerosis. 82 Although the main randomized controlled trial (the Women's Health Initiative) did not confirm the preventive action of estrogens against coronary heart disease, women who initiated hormone therapy closer to menopause tended to have reduced coronary heart disease risk, compared with the increase in coronary heart disease risk evident among women more distant from menopause. Interestingly, animal models mimic this discrepancy well, because both mouse and primate studies have revealed that the efficacy of estrogens on the prevention of plaque progression was inversely related to the duration of the estrogen-deprivation period after ovariectomy. The goal of the present study was to further define the cellular target(s) of the beneficial action of estradiol in early atheroma. Inactivation of estrogen receptor-␣ in endothelial cells of hypercholesterolemic mice completely abolished the atheroprotective action of estradiol, whereas hematopoietic estrogen receptor-␣ was dispensable. Thus, endothelial estrogen receptor-␣ represents a key target of the atheroprotective effect of estradiol, and selective estrogen receptor modulators that mimic the endothelial action of estradiol should now be considered in atheroprotection. The mechanisms responsible for the lack of beneficial action of estrogens in advanced atheroma remain to be elucidated.
We demonstrate directly and for the first time that endothelial estrogen receptor-␣ (ER␣) represents a key target of the atheroprotective effect of estradiol, whereas hematopoietic ER␣ is dispensable. Selective estrogen receptor modulators that mimic the endothelial action of estradiol should now be considered in atheroprotection. 83
Prevention of Cardiac Dysfunction in Acute Coxsackievirus B3 Cardiomyopathy by Inducible Expression of a Soluble Coxsackievirus-Adenovirus Receptor
Summary: Group B coxsackieviruses (CVBs) are the prototypical agents of acute myocarditis in humans, but an effective targeted therapy is not yet available. Acute enteroviral myocarditis may not lead to initial mortality but often results in the insidious development of chronic dilated cardiomyopathy and terminal heart failure. Here, we analyze the therapeutic potential of a soluble (s) virus receptor molecule against CVB3 myocarditis, delivered by use of a gene therapy approach. We generated an inducible adenoviral vector (AdG12) for strictly drug (doxycycline)-dependent delivery of sCAR-Fc, a fusion protein composed of the coxsackievirusadenovirus receptor (CAR) extracellular domain and the carboxyl terminus of human IgG1-Fc. After intravenous injection, AdG12 significantly improved systolic and diastolic function in CVB3infected mice if sCAR-Fc expression was pharmacologically induced in a prophylactic or therapeutic setting. Importantly, the hemodynamics of animals treated with AdG12 were similar to those of healthy control animals. With respect to the underlying pathomechanism, sCAR-Fc completely blocked (prophylactic) or strongly reduced (therapeutic) cardiac CVB3 infection and the resultant myocardial injury and inflammation. The strength of the cardioprotective effect and the additional safety feature mediated by the strict drug dependency of the sCAR-Fc expression make this strategy a promising approach for treatment of this life-threatening cardiac disease. It may also serve as a paradigm for analogous treatments of other severe viral infections by systemic delivery of "virus-trap" proteins, generated either by vectors as described here or by direct intravenous infusion of the encoded recombinant protein.
Conclusion: AdG12-mediated sCAR-Fc delivery prevents cardiac dysfunction in CVB3 myocarditis under prophylactic and therapeutic conditions. 84
CC Chemokine Receptor-1 Activates Intimal Smooth Muscle-Like Cells in Graft Arterial Disease
Summary: Graft arterial disease (GAD) remains a clinically important limitation to human cardiac transplantation. Five-year and 10-year patient survival rates after adult heart transplantation are 74% and 52%, respectively. Intravascular ultrasound demonstrates GAD in 75% of patients at 3 years after transplantation. Intimal smooth muscle-like cells (SMLCs) predominate in GAD lesions. Ischemia-reperfusion, allospecific humoral and cellular effectors, donor and host antigen-presenting cells, and atherogenic factors contribute to the intimal lesion formation. Chemokines affect GAD formation because they contribute to ischemia-reperfusion injury and acute rejection; however, chemokines can also contribute directly to vascular remodeling and angiogenesis beyond their role in leukocyte chemotaxis. Intimal SMLCs likely have multiple sources beyond simple recruitment from donor medial cells. Intimal SMLCs are clonal and phenotypically distinct from medial smooth muscle cells; SMLCs express hematopoietic markers such as CD14, CD34, CD105, Thy-1, c-kit, flt1, and flt-3. Bone marrow-derived or any other circulating precursor cell must access grafts from the circulation; the presence of smooth muscle progenitor cells in human peripheral blood corroborates this notion. We hypothesized that SMLC receptors and their cognate ligands promote intimal lesion formation. Such receptors must preferentially target SMLCs compared with intrinsic arterial smooth muscle cells. The present study demonstrates that RANTES can potentiate the effects of proliferative signals and implies that chemokines contribute to both the recruitment and expansion of intimal cells in GAD lesions. Clinical application will require further studies to evaluate the effect of CC chemokine receptor-1 depletion and immunosuppressive therapy, alone or in combination, on allograft rejection and GAD.
Conclusions: These studies provide a novel mechanistic insight into the formation of vascular intimal hyperplasia and suggest a novel therapeutic strategy for preventing allograft arteriopathy. 85 mulate excess cholesterol. This study provides evidence that expression of the major mediator of cholesterol removal from cells and the rate-limiting protein in new high-density lipoprotein particle formation, ATP-binding cassette transporter A1 (ABCA1), is reduced in intima-type cultured SMCs, in human coronary atherosclerotic intima, and specifically in atherosclerotic intimal SMCs. Remarkably, overexpression of ABCA1 in cultured intima-type SMCs failed to correct the binding of the main protein of high-density lipoprotein, apolipoprotein A-I, to the cells or cholesterol efflux from these cells. These results provide a previously unknown explanation for the accumulation of excess cholesterol in intimal smooth muscle foam cells and suggest that differences in gene and protein expression by medial and intimal SMCs might identify apolipoprotein A-I binding factors required for new high-density lipoprotein particle formation. Identification of these factors would provide novel targets for raising high-density lipoprotein clinically for the prevention of atherosclerosis.
Conclusion: ABCA1 expression is reduced in cultured model intimal and human atherosclerotic lesion SMCs, suggesting that reduced ABCA1 activity contributes to smooth muscle foam cell formation in the intima. 87
Int6/eIF3e Silencing Promotes Functional Blood Vessel Outgrowth and Enhances Wound Healing by Upregulating Hypoxia-Induced Factor 2␣ Expression
Summary: During the past decades, several studies have tried to trigger revascularization by exogenously applying angiogenic factors into the tissues of interest. A common obstacle was that the application of the specific angiogenic factor alone or an unbalanced combination with others led to the development of unphysiological and incomplete leaky blood vessels. In our research, we first found that hypoxia-inducible factor 2␣ is under subtype-specific and negative regulation of INT6, which directly binds to hypoxiainducible factor 2␣ and triggers its degradation through the proteasome pathway. Further in vivo experiments revealed that Int6 silencing led to enhancement of hypoxia-inducible factor 2␣ activity even under normoxic condition, temporarily inducing a physiological and potent neovascularization. In mouse skin, we determined subcutaneous fibroblasts as the major source of angiogenic factors. The fibroblasts treated ex vivo with siRNA-Int6 demonstrated that transplantation into the skin also led to the same strong induction of physiological neovascularization. Further application of siRNA-Int6 in a wound healing model (normal and db/db mice) showed a significantly enhanced wound repair with concomitant formation of new vessels. These results prefigure an encouraging therapeutic value of siRNA-Int6 for treating delayed wound healing, especially in diabetic patients with impaired microcirculation. Therefore, siRNA-Int6 -transfected fibroblast cell treatment or direct application of siRNA-Int6 might be of clinical value in treating ischemic diseases such as heart and brain ischemia, skin injury, and diseases involving obstructed vessels.
Conclusions:
We suggest that the pathway involving INT6/HIF2␣ acts as a hypoxia-independent master switch of functional angiogenesis; therefore, siRNA-Int6 application might be of clinical value in treating ischemic diseases such as heart and brain ischemia, skin injury, and diseases involving obstructed vessels. 88
Loss of Cardiac Phosphoinositide 3-Kinase p110␣ Results in Contractile Dysfunction
Summary: Small molecule inhibitors of phosphatidylinositol 3-kinases are currently being tested in early clinical trials for treatment of cancer. These drugs inhibit all 4 phosphatidylinositol 3-kinase catalytic isoforms, including p110␣. Results from this study show that inhibition of p110␣ in cardiac myocytes reduces the ion current through the L-type Ca 2ϩ channel. Because the L-type Ca 2ϩ current regulates myocyte contraction, treating patients with cancer who have underlying heart problems with nonselective phosphatidylinositol 3-kinase inhibitors might lead to deleterious cardiac side effects.
Conclusions: PI3K p110␣ but not p110␤ regulates the L-type Ca 2ϩ channel (LTCC) in cardiac myocytes. Decreased signaling to p110␣ reduces the number of LTCCs on the cell surface and thus attenuates ICa,L and contractility. 89
Molecular and Functional Characterization of a Novel Cardiac-Specific Human Tropomyosin Isoform
Summary: Understanding the function of tropomyosin (TM) is important from a clinical perspective because mutations in the protein can result in familial hypertrophic cardiomyopathy and dilated cardiomyopathy. Four TM genes have been identified, each of which undergoes differential promoter usage and alternative splicing to generate multiple isoforms. In the heart, TM is an essential sarcomeric protein that controls calcium-regulated muscle contraction. Although much is known about TM, little is known about its expression in human hearts. In this study, we determine and quantify the expression levels of striated muscle TM isoforms in the human heart, including a novel TM isoform called TPM1. Our data show that TPM1 is incorporated into cardiac myofilaments, and its level increases by 100% during human dilated cardiomyopathy and heart failure. We also develop a mouse model to understand the physiological function of TPM1. Because there is 100% amino acid sequence identity between human and mouse TM, these studies have direct relevance to TM function. Our mouse model shows that increased expression of TPM1 results in increased end-systolic and end-diastolic left ventricular dimensions, similar to patients with dilated cardiomyopathy. Physiological assessment of the hearts from our mouse model show decreased fractional shortening, systolic and diastolic dysfunction, and decreased myofilament calcium sensitivity, which is similar to patients with heart disease. These studies provide a possible mechanism for the clinical features that are observed in dilated cardiomyopathy and heart failure patients.
Conclusions: This functional analysis of TPM1 provides a possible mechanism for the consequences of the TM isoform switch observed in dilated cardiomyopathy and heart failure patients. 90
Three-Dimensional and Molecular Analysis of the Venous Pole of the Developing Human Heart
Summary: The morphologically complex venous pole of the postnatal human heart, consisting of the union of the caval veins with the right atrium, the coronary sinus, and the connection of the pulmonary veins with the left atrium, is a clinically important entity. Although rare, many forms of congenital heart disease locate at the venous pole of the heart and influence the hemodynamics by changing the quantity and direction of blood inflow. In addition, many abnormal rhythms such as focal atrial tachycardia and paroxysmal atrial fibrillation have been shown to originate from the myocardium making up part of the venous pole. In particular, the hypothesis that the myocardial sleeves of the systemic and pulmonary venous returns have a common origin has been used to explain the nonrandom location of the arrhythmogenic foci at the venous pole. In agreement with gene expression and lineage studies performed in mice that have shown that the myocardium of the systemic and pulmonary veins develops from genetically distinct cellular populations, the present study in human embryonic hearts reveal distinct transcriptional profiles in the myocardium surrounding the systemic and pulmonary returns. The similarity of these transcriptional signatures in mice and humans suggests evolutionary conservation of the genetic program for the formation of these compartments at the venous pole, lends no support to the notion that the pulmonary myocardium originates from
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the systemic venous sinus, and suggests another mechanism for the origin of the electric impulses initiating paroxysms of atrial fibrillation within the pulmonary venous sleeves.
Conclusion:
The similarities in gene expression in the distinctive types of myocardium surrounding the systemic and pulmonary venous tributaries in man and mouse permit extrapolation of the conclusions drawn from transgenic and lineage studies in the mouse to the human, showing that the systemic and pulmonary venous myocardial sleeves are derived from distinct developmental lineages. 91
Vascular Endothelial-Specific Dimethylarginine Dimethylaminohydrolase-1-Deficient Mice Reveal That Vascular Endothelium Plays an Important Role in Removing Asymmetrical Dimethylarginine
Summary: Asymmetrical methylarginines asymmetrical dimethylarginine (ADMA) and NG-monomethyl-L-arginine are endogenous NO synthase inhibitors. Recent clinical studies demonstrated that the elevation of ADMA levels is associated with many pathological conditions. Thus, ADMA becomes an independent risk indicator for cardiovascular diseases. Asymmetrical methylarginines are eliminated from the body mainly through degradation by dimethylarginine dimethylaminohydrolase (DDAH). Thus, impaired DDAH activity due to either loss-of-function polymorphisms of the DDAH gene or posttranslational modification of DDAH protein may cause accumulation of asymmetrical methylarginines. In this study, we found that endothelial-specific depletion of DDAH1 in endo-DDAH1 Ϫ/Ϫ mice leads to increases of plasma and tissue ADMA concentration and systemic blood pressure, as well as decrease of acetylcholine-induced NO generation and vasodilation in the isolated vessel rings. These results demonstrated that endothelial DDAH1 plays an important role in metabolizing ADMA and regulating blood pressure and vessel tone. In addition, the endo-DDAH1 Ϫ/Ϫ and the DDAH1 flox/flox mouse strains will become useful tools for studies of the NO signaling pathway in various tissues under physiological or pathological conditions.
Conclusions:
Our study demonstrates that DDAH1 is highly expressed in vascular endothelium and that endothelial DDAH1 plays an important role in regulating blood pressure. In the context that asymmetrical methylarginines are broadly produced by many type of cells, the strong DDAH1 expression in vascular endothelium demonstrates for the first time that vascular endothelium can be an important site to actively dispose of toxic biochemical molecules produced by other types of cells. 92
Impaired Autonomic Regulation of Resistance Arteries in Mice With Low Vascular Endothelial Growth Factor or On Vascular Endothelial Growth Factor Trap Delivery
Summary: Vascular endothelial growth factor (VEGF) is a key angiogenic factor, and blocking of VEGF signaling in cancer patients inhibits angiogenesis, thereby preventing tumor progression. One of the side effects of anti-VEGF therapy is the hand-foot syndrome, which is characterized by dilated blood vessels in hands and feet, leading to dysesthesia, erythema, and tingling of extremities, which may progress to burning pain with dryness, cracking, and ulceration of the skin. Here, we show that knock-in mice with reduced VEGF levels display abnormal regulation of resistance arteries, resulting in defects in thermoregulation and redistribution of blood flow in response to hypoxia. The abnormal vascular regulation was attributed to reduced vascular smooth muscle cell contractility associated with reduced expression of contractile proteins, as well as to dysfunction of neuroeffector junctions as a result of their abnormal structural development. Furthermore, short-term treatment of wild-type mice with a VEGF trap also induced thermoregulation defects and neuroeffector dysfunction with structural remodeling of neuroeffector junctions, indicating that VEGF is necessary for maintenance of the structural and functional integrity of adult neuroeffector junctions. These findings may provide mechanistic insights into the cause of the hand-foot syndrome.
Conclusions: These findings uncover a novel role for VEGF in the maintenance of arterial neuroeffector function and may help us better understand how VEGF inhibitors cause vascular regulation defects in cancer patients. 93
Transcription Factor Fos-Related Antigen-2 Induces Progressive Peripheral Vasculopathy in Mice Closely Resembling Human Systemic Sclerosis
Summary: Microvascular alterations are one of the earliest phenomena in the pathophysiology of systemic sclerosis. However, the molecular mechanisms initiating and perpetuating the peripheral vasculopathy are unknown. In this study, we show that Fra-2 transgenic mice display various features of the peripheral vasculopathy of human systemic sclerosis with a reduction in capillaries and early apoptosis of endothelial cells. Furthermore, this animal model combines clinically evident peripheral and pulmonary vasculopathy with fibrosis of the skin and internal organs, particularly the lungs. We could also demonstrate that apoptosis of endothelial cells occurs before the manifestation of fibrosis and contributes to the reduction in capillary density in later stages of the model as supposed for human systemic sclerosis. Therefore, Fra-2 transgenic mice can be proposed as an excellent preclinical model that allows us to study the link between vasculopathy and fibrosis. This model also enables the testing of antifibrotic agents and drugs targeting vasculopathy simultaneously. Because we provide evidence that Fra-2 is present in human systemic sclerosis, Fra-2 might also represent a promising future target to treat both vasculopathy and fibrosis in systemic sclerosis patients.
Conclusions: Fra-2 is present in human systemic sclerosis and may contribute to the development of microvasculopathy by inducing endothelial cell apoptosis and by reducing endothelial cell migration and chemotaxis. Fra-2 transgenic mice are a promising preclinical model to study the mechanisms and therapeutic approaches of the peripheral vasculopathy in systemic sclerosis. 94 
